



## Xeomin® (incobotulinumtoxinA) Bibliography

### THERAPEUTIC USES

[ADULT SPASTICITY](#)

[BLEPHAROSPASM](#)

[CERVICAL DYSTONIA](#)

[CHRONIC SIALORRHEA](#)

[GENITOURINARY](#)

[HEMIFACIAL SPASM](#)

[HYPERHIDROSIS](#)

[MIGRAINE](#)

[OPHTHALMOLOGY USES OTHER THAN BENIGN ESSENTIAL BLEPHAROSPASM](#)

[ORTHOPEDICS/REHABILITATION MEDICINE](#)

[PAIN](#)

[PARKINSON'S DISEASE TREMOR AND ESSENTIAL TREMOR](#)

[PEDIATRIC SPASTICITY](#)

[TEMPOROMANDIBULAR JOINT DISORDER \(TMJ\), FACIAL PAIN, AND/OR FACIAL PALSY](#)

[OTHER CONDITIONS](#)

### ADDITIONAL INFORMATION

[FLEXIBLE/INDIVIDUALIZED INJECTION SCHEME](#)

[PHARMACOECONOMICS](#)

[IMMUNOGENICITY](#)

[SAFETY](#)

[CLINICAL PHARMACOLOGY](#)

[NONCLINICAL COMPARISON](#)

## THERAPEUTIC USES

### Adult Spasticity

#### *Upper Limb Spasticity*

1. Picelli A, Tamburin S, Di Censo R, Smania N, Filippetti M. Does the diffusion profile differ between botulinum toxin type A formulations? Implications for the management of post-stroke spasticity. *Toxins (Basel)*. 2024;16(11):480.
2. Falcone N, Leo F, Chisari C, Dalise S. Long-term management of post-stroke spasticity with botulinum toxin: a retrospective study. *Toxins (Basel)*. 2024;16(9):383.
3. Filippetti M, Tamburin S, Di Censo R, et al. Do diagnostic nerve blocks affect the starting dose of botulinum neurotoxin type A for spasticity? A case-control study. *Toxins (Basel)*. 2024;16(9):388.
4. Heckert K, Biering-Sørensen B, Bäumer T, et al. Delphi analysis: optimizing anatomy teaching and ultrasound training for botulinum neurotoxin type A injection in spasticity and dystonia. *Toxins (Basel)*. 2024;16(8):371.
5. Marano M, Suppa A, Palmieri MG, et al. Comprehensive Observational and Longitudinal study on the Outbreak of Stroke-related Spasticity focusing on the Early Onset management with Botulinum NeuroToxin (COLOSSEO-BoNT): protocol for a real-world prospective observational study on upper limb spasticity. *BMJ Open*. 2024;14(6):e085484.
6. Reebye R, Jacinto LJ, Balbert A, et al. Multimodal therapy and use of adjunctive therapies to BoNT-A in spasticity management: defining terminology to help enhance spasticity treatment. *Front Neurol*. 2024;15:1432330.
7. Molteni F, Wissel J, Fheodoroff K, et al. Improvement in quality-of-life-related outcomes following treatment with incobotulinumtoxinA in adults with limb spasticity: a pooled analysis. *Toxins*. 2024;16(1):19.
8. Camoes-Barbosa A. Efficacy of incobotulinumtoxinA for spasticity-associated pain in a series of patients with spasticity of diverse etiologies. *Med Res Arch*. 2023;11(5).
9. Intiso D, Centra AM, Gravina M, Chiaramonte A, Bartolo M, Di Rienzo F. Botulinum toxin-A high-dosage effect on functional outcome and spasticity-related pain in subjects with stroke. *Toxins (Basel)*. 2023;15(8):509.
10. Marvulli R, Ranieri M, Rizzo LB, et al. Clinical onset of action of incobotulinum toxin A preparation. *CNS Neurol Disord Drug Targets*. 2023;22(6):916-923.
11. Struyf P, Triccas LT, Schillebeeckx F, Struyf F. The place of botulinum toxin in spastic hemiplegic shoulder pain after stroke: a scoping review. *Int J Environ Res Public Health*. 2023;20(4):2797.
12. Trompetto C, Marinelli L, Mori L, et al. Increasing the passive range of joint motion in stroke patients using botulinum toxin: the role of pain relief. *Toxins (Basel)*. 2023;15(5):335.
13. Wissel J, Songjin R, Kivi A. Early versus late injections of botulinumtoxin type A in post-stroke spastic movement disorder: a literature review. *Toxicon*. 2023;229:107150.
14. Battaglia M, Borg MB, Torgano L, et al. The lack of systemic and subclinical side effects of botulinum neurotoxin type-A in patients affected by post-stroke spasticity: a longitudinal cohort study. *Toxins (Basel)*. 2022;14(8):564.

15. Del Prete CM, Viva MG, De Trane S, et al. An observational cross-sectional study of gender and disability as determinants of person-centered medicine in botulinum neurotoxin treatment of upper motoneuron syndrome. *Toxins (Basel)*. 2022;14(4):246.
16. Jacinto J, Camões-Barbosa A, Carda S, Hoad D, Wissel J. A practical guide to botulinum neurotoxin treatment of shoulder spasticity 1: Anatomy, physiology, and goal setting. *Front Neurol*. 2022;13:1004629.
17. Masakado Y, Dekundy A, Tateishi S, Kaji R. IncobotulinumtoxinA for post-stroke upper limb spasticity in neutralizing antibody-positive patients after botulinum toxin therapy: a report of two cases. *Prog Rehabil Med*. 2022;7:20220012.
18. Novarella F, Carotenuto A, Cipullo P, et al. Persistence with botulinum toxin treatment for spasticity symptoms in multiple sclerosis. *Toxins (Basel)*. 2022;14(11):774.
19. Teuschl Y, Bancher C, Brainin M, Dachenhausen A, Matz K, Pinter MM. COVID-19-related delays of botulinum toxin injections have a negative impact on the quality of life of patients with dystonia and spasticity: a single-center ambulatory care study. *J Neural Transm (Vienna)*. 2022;129(1):49-53.
20. Trompetto C, Marinelli L, Mori L, et al. Effectiveness of botulinum toxin on pain in stroke patients suffering from upper limb spastic dystonia. *Toxins (Basel)*. 2022;14(1):39.
21. Wissel J, Camões-Barbosa A, Carda S, Hoad D, Jacinto J. A practical guide to botulinum neurotoxin treatment of shoulder spasticity 2: Injection techniques, outcome measurement scales, and case studies. *Front Neurol*. 2022;13:1022549.
22. Macher S, Unger E, Zalaudek M, et al. Denervation dynamics after intramuscular BNT injection in patients with focal spasticity monitored by MRI and dynamometry—a blinded randomized controlled pilot study. *Front Neurol*. 2021;12:719030.
23. Turcu-Stiolica A, Subtirelu MS, Bumbea AM. Can incobotulinumtoxin-A treatment improve quality of life better than conventional therapy in spastic muscle post-stroke patients? Results from a pilot study from a single center. *Brain Sci*. 2021;11(7):934.
24. Wissel J, Camões-Barbosa A, Comes G, Althaus M, Scheschonka A, Simpson DM. Pain reduction in adults with limb spasticity following treatment with incobotulinumtoxinA: a pooled analysis. *Toxins (Basel)*. 2021;13(12):887.
25. Fheodoroff K, Rekan T, Medeiros L, et al. Quality of life in subjects with upper- and lower-limb spasticity treated with incobotulinumtoxinA. *Health Qual Life Outcomes*. 2020;18(1):51.
26. Kagaya H, Masakado Y, Saitoh E, et al. IncobotulinumtoxinA for upper- and lower-limb spasticity in Japanese patients. *Curr Med Res Opin*. 2020;36(5):827-834.
27. Kirshblum S, Solinsky R, Jasey N, et al. Adverse event profiles of high dose botulinum toxin injections for spasticity. *PM R*. 2020;12(4):349-355.
28. Marciniak C, Munin MC, Brashear A, et al. IncobotulinumtoxinA treatment in upper-limb poststroke spasticity in the open-label extension period of pure: efficacy in passive function, caregiver burden, and quality of life. *PM R*. 2020;12(5):491-499.
29. Masakado Y, Abo M, Kondo K. Efficacy and safety of incobotulinumtoxinA in post-stroke upper-limb spasticity in Japanese subjects: results from a randomized, double-blind, placebo-controlled study (J-PURE). *J Neurol*. 2020;267(7):2029-2041.
30. Moccia M, Frau J, Carotenuto A, et al. Botulinum toxin for the management of spasticity in multiple sclerosis: the Italian botulinum toxin network study. *Neurol Sci*. 2020;41(10):2781-2792.

31. Wissel J, Bensmail D, Scheschonka A, et al. Post hoc analysis of the improvement in shoulder spasticity and safety observed following treatment with incobotulinumtoxinA. *J Rehabil Med*. 2020;52(3):jrm00028.
32. Amatya B, Cofré Lizama LE, Elmalik A, Bastani A, Galea MP, Khan F. Multidimensional evaluation of changes in limb function following botulinum toxin injection in persons with stroke. *NeuroRehabilitation*. 2019;45(1):67-78.
33. Andringa A, van de Port I, van Wegen E, Ket J, Meskers C, Kwakkel G. Effectiveness of botulinum toxin treatment for upper limb spasticity poststroke over different ICF domains: a systematic review and meta-analysis. *Arch Phys Med Rehabil*. 2019;100(9):1703-1725.
34. Iskra DA, Kovalenko AP, Koshkarev MA, Frunza DN. Kombinatsiia miorelaksantov tsentral'nogo i perifericheskogo deistviia v lechenii postinsul'tnoī spastichnosti [Combination of central and peripheral muscle relaxants in the treatment of post-stroke spasticity]. *Zh Nevrol Psikhiatr Im S Korsakova*. 2019;119(12. Vyp. 2):51-57. [Article in Russian]
35. Marciniak C, Munin MC, Brashear A, et al. IncobotulinumtoxinA efficacy and safety in adults with upper-limb spasticity following stroke: results from the open-label extension period of a phase 3 study. *Adv Ther*. 2019;36(1):187-199.
36. van Lith BJH, den Boer J, van de Warrenburg BPC, Weerdesteyn V, Geurts AC. Functional effects of botulinum toxin type A in the hip adductors and subsequent stretching in patients with hereditary spastic paraplegia. *J Rehabil Med*. 2019;51(6):434-441.
37. Büyükavcı R, Büyükavcı MA. Effects of ultrasound-guided botulinum toxin type-A injections with a specific approach in spastic cerebral palsy. *Acta Neurol Belg*. 2018;118(3):429-433.
38. Dressler D, Pan L, Bigalke H. Comparing incobotulinumtoxinA (Xeomin®) and onabotulinumtoxinA (Botox®): identical potency labeling in the hemidiaphragm assay. *J Neural Transm (Vienna)*. 2018;125(9):1351-1354.
39. Ianieri G, Marvulli R, Gallo G, Fiore P, Megna M. Appropriate treatment and therapeutic window in spasticity treatment with incobotulinumtoxinA: from 100 to 1000 units. *Toxins (Basel)*. 2018;10(4):140.
40. Gallien P, Leblong E, Fraudet B, et al. Therapeutic benefit of botulinum toxin A (incobotulinum toxin) for the treatment of spasticity of the triceps surae in multiple sclerosis: an observational study. *Phys Med Rehabil Int*. 2017;4(6):1133.
41. Wissel J, Bensmail D, Ferreira J, et al. Safety and efficacy of incobotulinumtoxinA doses up to 800 U in limb spasticity: The Tower Study. *Neurology*. 2017;88(14):1321-1328.
42. Elovic EP, Munin MC, Kaňovský P, Hanschmann A, Hiersemenzel R, Marciniak C. Randomized, placebo-controlled trial of incobotulinumtoxinA for upper-limb post-stroke spasticity. *Muscle Nerve*. 2016;53(3):415-421.
43. Lamb YN, Scott LJ. IncobotulinumtoxinA: a review in upper limb spasticity. *Drugs*. 2016;76(14):1373-1379.
44. Santamato A. Safety and efficacy of incobotulinumtoxinA as a potential treatment for poststroke spasticity. *Neuropsychiatr Dis Treat*. 2016;12:251-263.
45. Scaglione F. Conversion ratio between Botox®, Dysport®, and Xeomin® in clinical practice. *Toxins (Basel)*. 2016;8(3):65.
46. Zeuner KE, Deuschel G. Pharmacokinetics and pharmacodynamics of incobotulinumtoxin A influencing the clinical efficacy in post-stroke spasticity. *Expert Opin Drug Metab Toxicol*. 2016;12(4):457-466.

47. Dressler D, Adib Saberi F, Kollewe K, Schrader C. Safety aspects of incobotulinumtoxinA high-dose therapy. *J Neural Transm.* 2015;122(2):327-333.
48. Santamato A, Micello MF, Panza F, et al. Adhesive taping vs. daily manual muscle stretching and splinting after botulinum toxin type A injection for wrist and fingers spastic overactivity in stroke patients: a randomized controlled trial. *Clin Rehabil.* 2015;29(1):50-58.
49. Intiso D, Simone V, Di Rienzo F, et al. High doses of a new botulinum toxin type A (NT-201) in adult patients with severe spasticity following brain injury and cerebral palsy. *NeuroRehabilitation.* 2014;34(3):515-522.
50. Santamato A, Micello MF, Panza F, et al. Can botulinum toxin type A injection technique influence the clinical outcome of patients with post-stroke upper limb spasticity? A randomized controlled trial comparing manual needle placement and ultrasound-guided injection techniques. *J Neurol Sci.* 2014;347(1-2):39-43.
51. Bensmail D, Hanschmann A, Wissel J. Satisfaction with botulinum toxin treatment in post-stroke spasticity: results from two cross-sectional surveys (patients and physicians). *J Med Econ.* 2014;17(9):618-625.
52. Santamato A, Panza F, Ranieri M, et al. Efficacy and safety of higher doses of botulinumtoxin type A NT 201 free from complexing proteins in the upper and lower limb spasticity after stroke. *J Neural Transm.* 2013;120(3):469-476.
53. Turner-Stokes L, Fheodoroff K, Jacinto J, Maisonobe P. Results from the Upper Limb International Spasticity Study-II (ULIS-II): A large, international, prospective cohort study investigating practice and goal attainment following treatment with botulinum toxin A in real-life clinical practice. *BMJ Open.* 2013;3(6):e002771.
54. Turner-Stokes L, Fheodoroff K, Jacinto J, Maisonobe P, Zakine B. Upper limb international spasticity study: rationale and protocol for a large, international, multicentre prospective cohort study investigating management and goal attainment following treatment with botulinum toxin A in real-life clinical practice. *BMJ Open.* 2013;3(3):e002230.
55. Falso M, Galluso R, Malvicini A. Functional influence of botulinum neurotoxin type A treatment (Xeomin®) of multifocal upper and lower limb spasticity on chronic hemiparetic gait. *Neurol Int.* 2012;4(e8):32-34.
56. Fiore P, Santamato A, Ranieri M, et al. Treatment of upper limb spasticity after stroke: one-year safety and efficacy of botulinum toxin type A NT201. *Int J Immunopathol Pharmacol.* 2012;25(suppl 1):57S-62S.
57. Hesse S, Mach H, Fröhlich S, Behrend S, Werner C, Melzer I. An early botulinum toxin A treatment in subacute stroke patients may prevent disabling finger flexor stiffness six months later: a randomized controlled trial. *Clin Rehabil.* 2012;26(3):237-245.
58. Kostenko EV, Petrova LV, Ganzhula PA, et al. [Experience in using Xeomin in the treatment of arm and hand spasticity in the early rehabilitation phase of stroke]. *Zh Nevrol Psikhiatr Im S Korsakova.* 2012;112:29-34. [Article in Russian]
59. Santamato A, Ranieri M, Panza F, et al. Effectiveness of switching therapy from complexing protein-containing botulinum toxin type A to a formulation with low immunogenicity in spasticity after stroke: a case report. *J Rehabil Med.* 2012;44:795-797.
60. Villafañe JH, Silva GB, Chiarotto A, Ragusa OLF. Botulinum toxin type A combined with neurodynamic mobilization for upper limb spasticity after stroke: a case report. *J Chiropr Med.* 2012;11:186-191.

61. Kaňovský P, Slawek J, Denes Z, et al. Efficacy and safety of treatment with incobotulinum toxin A (botulinum neurotoxin type A free from complexing proteins; NT 201) in post-stroke upper limb spasticity. *J Rehabil Med.* 2011;43(6):486-492.
62. Barnes M, Schnitzler A, Medeiros L, Aguilar M, Lehnert-Batar A, Minnasch P. Efficacy and safety of NT 201 for upper limb spasticity of various etiologies--a randomized parallel-group study. *Acta Neurol Scand.* 2010;122(4):295-302.
63. Khatkova SE. [Xeomin in the treatment of post stroke spasticity]. *Zh Nevrol Psikhiatr Im S Korsakova.* 2010;110(8):62-64.
64. Santamato A, Panza F, Filoni S, et al. Effect of botulinum toxin type A, motor imagery and motor observation on motor function of hemiparetic upper limb after stroke. *Brain Inj.* 2010;24(9):1108-1112.
65. Dressler D. Routine use of Xeomin in patients previously treated with Botox: long term results. *Eur J Neurol.* 2009;16(suppl 2):2-5.
66. Kaňovský P, Slawek J, Denes Z, et al. Efficacy and safety of botulinum neurotoxin NT 201 in post stroke upper limb spasticity. *Clin Neuropharmacol.* 2009; 32(5):259-265.

#### *Lower Limb Spasticity*

1. Falcone N, Leo F, Chisari C, Dalise S. Long-term management of post-stroke spasticity with botulinum toxin: a retrospective study. *Toxins (Basel).* 2024;16(9):383.
2. Filippetti M, Tamburin S, Di Censo R, et al. Do diagnostic nerve blocks affect the starting dose of botulinum neurotoxin type A for spasticity? A case-control study. *Toxins (Basel).* 2024;16(9):388.
3. Cotinat M, Celerier M, Arquillière C, et al. Robotic gait training and botulinum toxin injection improve gait in the chronic post-stroke phase: a randomized controlled trial. *Ann Phys Rehabil Med.* 2024;67(1):101785
4. Camoes-Barbosa A. Efficacy of incobotulinumtoxinA for spasticity-associated pain in a series of patients with spasticity of diverse etiologies. *Med Res Arch.* 2023;11(5).
5. Masakado Y, Kagaya H, Kondo K, et al. Efficacy and safety of incobotulinumtoxinA in the treatment of lower limb spasticity in Japanese subjects. *Front Neurol.* 2022;13:832937.
6. Bensmail D, Wissel J, Laffont I, et al. Efficacy of incobotulinumtoxinA for the treatment of adult lower-limb post-stroke spasticity, including pes equinovarus. *Ann Phys Rehabil Med.* 2021;64(2):101376.
7. Cordero-García C, Sáenz De Tejada Sánchez MDM. Benefit and safety of incobotulinumtoxinA for early management of post-stroke spasticity in a patient with SARS-CoV-2: a case report. *J Rehabil Med Clin Commun.* 2021;4:1000065.
8. Woo J, Mas MF, Zhang J, et al. Real-world analysis of botulinum toxin (BoNT) injections in post-stroke spasticity: higher doses of BoNT and longer intervals in the early-start group. *J Neurol Sci.* 2021;425:117449.
9. Fheodoroff K, Rekan T, Medeiros L, et al. Quality of life in subjects with upper- and lower-limb spasticity treated with incobotulinumtoxinA. *Health Qual Life Outcomes.* 2020;18(1):51.

10. Marvulli R, Megna M, Citraro A, et al. Botulinum toxin type A and physiotherapy in spasticity of the lower limbs due to amyotrophic lateral sclerosis. *Toxins (Basel)*. 2019;11(7):381.
11. Santamato A, Cinone N, Panza F, et al. Botulinum toxin type A for the treatment of lower limb spasticity after stroke. *Drugs*. 2019;79(2):143-160.
12. Sun LC, Chen R, Fu C, et al. Efficacy and safety of botulinum toxin type A for limb spasticity after stroke: a meta-analysis of randomized controlled trials. *Biomed Res Int*. 2019;2019:8329306.
13. Ianieri G, Marvulli R, Gallo GA, Fiore P, Megna M. "Appropriate treatment" and therapeutic window in spasticity treatment with inco-BoNT/A: from 100 to 1000 units. *Toxins (Basel)*. 2018;10(4):E140.
14. Rieu I, Degos B, Castelnovo G, et al. Incobotulinum toxin A in Parkinson's disease with foot dystonia: a double-blind randomized trial. *Parkinsonism Relat Disord*. 2018;46:9-15.
15. Santamato A, Panza F, Intiso D, et al. Long-term safety of repeated high doses of incobotulinumtoxinA injections for the treatment of upper and lower limb spasticity after stroke. *J Neurol Sci*. 2017;378:182-186.
16. Wissel J, Bensmail D, Ferreira JJ, et al. Safety and efficacy of inco-BoNT/A doses up to 800 U in limb spasticity: The TOWER study. *Neurology*. 2017;88(14):1321-1328.
17. Chu WH, Gupta AD. Effectiveness of botulinum toxin type A on gait and quality of life in adult post-stroke patients with lower limb spasticity: a systematic review protocol. *JBIG Database of System Rev Implement Rep*. 2016;14(6):23-29.
18. Intiso D, Simone V, Di Rienzo F, Iarossi A, Paziienza L, et al. High doses of a new botulinum toxin type A (NT-201) in adult patients with severe spasticity following brain injury and cerebral palsy. *NeuroRehabilitation*. 2014; 34(3):515-522.
19. Santamato A, Micello MF, Panza F, et al. Safety and efficacy of incobotulinum toxin type A (NT 201-Xeomin) for the treatment of post-stroke lower limb spasticity: a prospective open-label study. *Eur J Phys Rehabil Med* 2013;49(1):1-7.
20. Santamato A, Panza F, Ranieri M, et al. Efficacy and safety of higher doses of botulinumtoxin type A NT 201 free from complexing proteins in the upper and lower limb spasticity after stroke. *J Neural Transm*. 2013;120(3):469-476.
21. Carda S, Invernizzi M, Baricich A, Cisari C. Casting, taping or stretching after botulinum toxin type A for spastic equines foot: a single-blind randomized trial on adult stroke patients. *Clin Rehabil*. 2011;25(11):1119-1127.
22. Lippert-Grüner M, Svestkova O. Early use of Xeomin neurotoxin for local anti-spasticity therapy for pes equines after acquired brain injury (ABI). *Brain Inj*. 2011;25(12):1266-1269.

### *Other Spasticity*

1. Turna I, Erhan B, Gunduz N, Turna O. The effects of different injection techniques of botulinum toxin A in post-stroke patients with plantar flexor spasticity. *Acta Neurol Belg*. 2020;120(3):639-643.
2. Erbil D, Tugba G, Murat T, et al. Effects of robot-assisted gait training in chronic stroke patients treated by botulinum toxin-A: a pivotal study. *Physiother Res Int*. 2018;23(3):e1718.

3. Alfonsi E, Restivo DA, Cosentino G, et al. Botulinum toxin is effective in the management of neurogenic dysphagia. clinical-electrophysiological findings and tips on safety in different neurological disorders. *Front Pharmacol.* 2017;8:80.
4. Mastromauro L, Trerotoli P, Romanelli E, Marvulli RG, Ianieri G. Incobotulinumtoxina (Xeomin<sup>®</sup>) versus onabotulinumtoxina (Botox<sup>®</sup>): evaluation of clinical onset of action with rating scales and electroneurography. *Int J Neurorehabilitation.* 2015;2(182):2376-0281.
5. Invernizzi M, Carda S, Molinari C, Stagno D, Cisari C, Baricich A. Heart rate variability (HRV) modifications in adult hemiplegic patients after botulinum toxin type A (NT-201) injection. *Eur J Phys Rehabil Med.* 2014;12.
6. Vainshenker YI, Ivchenko IM, Korotkov AD, Kataeva GV, Medvedev SV. Polyfunctionality of Neurons: the blocking of extreme pathological afferentation leads to an improvement of the higher functions of the brain. *Human Physiology.* 2013;39(1):19-21.
7. Santamato A, Panza F, Ranieri M, Amoroso MT, Amoroso L, Frisardi V, Solfrizzi V, Fiore P. Effects of intrathecal baclofen, botulinum toxin type A and a rehabilitation program on locomotor function after spinal cord injury: a case report. *J Rehabil Med.* 2010;42(9):891-894.

## Blepharospasm

1. Hast MA, Kong AM, Desai S, Back S, Syed S, Holmes J. Patient characteristics and real-world use of botulinum toxins for the treatment of cervical dystonia, blepharospasm, and hemifacial spasm. *Toxins (Basel).* 2024;16(8):362.
2. Jamison A, Favor M, Malhotra R. Patient-reported outcomes following a break in ophthalmic botulinum toxin therapy during the COVID-19 pandemic *Can J Ophthalmol.* 2024;59(1):e41-e45.
3. Yazdanpanah G, Yen MT, Pflugfelder SC. Quantitative assessment of botulinum toxin injection on blink rate in blepharospasm. *Orbit.* 2023;42(6):571-578.
4. Wenninger FC, Wabbels B. Frequency of hemorrhagic side effects of botulinum neurotoxin treatment in patients with blepharospasm and hemifacial spasm on antithrombotic medication. *Toxins (Basel).* 2022;14(11):769.
5. Kent R, Robertson A, Quiñones Aguilar S, Tzoulis C, Maltman J. Real-world dosing of onabotulinumtoxina and incobotulinumtoxinA for cervical dystonia and blepharospasm: results from TRUDOSE and TRUDOSE II. *Toxins (Basel).* 2021;13(7):488.
6. Mitsikostas DD, Dekundy A, Hanschmann A, et al. Duration and onset of effect of incobotulinumtoxinA for the treatment of blepharospasm in botulinum toxin-naïve subjects. *Curr Med Res Opin.* 2021;37(10):1761-1768.
7. Mitsikostas DD, Dekundy A, Sternberg K, et al. IncobotulinumtoxinA for the treatment of blepharospasm in toxin-naïve subjects: a multi-center, double-blind, randomized, placebo-controlled trial. *Adv Ther.* 2020;37:4249-4265.
8. Weiss D, Hieber L, Sturm J, et al. Health-related quality of life outcomes from botulinum toxin treatment in blepharospasm. *Clin Neurol Neurosurg.* 2018;172:130-133.
9. Defazio G, Hallett M, Jinnah H, Conte A, Berardelli A. Blepharospasm 40 Years Later. *Mov Disord.* 2017;32(4):498-509.

10. Fernandez HH, Jankovic J, Holds J, et al. XCiDaBLE: An observational, prospective trial evaluating Xeomin (incobotulinumtoxinA) for cervical dystonia or blepharospasm in the United States - Final results from the blepharospasm cohort. *Neurology*. 2015;84(suppl 14):P4.331.
11. Chundury R, Couch S, Holds J. Reply Re: "Comparison of preferences between onabotulinumtoxinA (Botox) and incobotulinumtoxinA (Xeomin) in the treatment of benign essential blepharospasm". *Ophthal Plast Reconstr Surg*. 2014;30(1):77.
12. Fernandez H, Jankovic J, Holds J, et al. Observational study of incobotulinumtoxinA for cervical dystonia or blepharospasm (XCiDaBLE): Interim results for the first 170 subjects with blepharospasm. *Tremor Other Hyperkinet Mov*. 2014;4:238.
13. Giacometti J, Yen MT. Re: "Comparison of preferences between onabotulinumtoxinA (Botox) and incobotulinumtoxinA (Xeomin) in the treatment of benign essential blepharospasm". *Ophthal Plast Reconstr Surg*. 2014;30(1):76-77.
14. Kollwe K, Mohammadi B, Köhler S, Pickenbrock H, Dengler R, Dressler D. Blepharospasm: long-term treatment with either Botox, Xeomin or Dysport. *J Neural Transm*. 2014;122(3):427-431.
15. Ricciardi L, Ialongo T, Guidubaldi A, Di Giacopo R, Bentivoglio A. Blepharospasm with non-satisfactory response to treatment: our experience with incobotulinumtoxinA. *Parkinsonism Relat Disord*. 2014;20(6):665-667.
16. Saad J, Gourdeau A. A direct comparison of onabotulinumtoxinA (Botox) and incobotulinumtoxinA (Xeomin) in the treatment of benign essential blepharospasm: a split-face technique. *J Neuro Ophthalmol*. 2014;34(3):233-236.
17. Chundury R, Chouch S, Hold J. Comparison of preferences between onabotulinumtoxinA (Botox) and incobotulinumtoxinA (Xeomin) in the treatment of benign essential blepharospasm. *Ophthal Plast Reconstr Surg*. 2013;29:205-207.
18. Roggenkämper P, Hauschke D. IncobotulinumtoxinA demonstrated equal efficacy to onabotulinumtoxinA in the treatment of blepharospasm. *The Botulinum J*. 2013;2:329.
19. Truong D, Gollomp S, Jankovic J, et al. Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin) injections in blepharospasm. *J Neural Transm*. 2013;120(9):1345-1353.
20. Park J, Lee M, Harrison A. Profile of Xeomin (incobotulinumtoxinA) for the treatment of blepharospasm. *Clin Ophthalmol*. 2011;5:725.
21. Wabbels B, Roggenkämper P. Essential blepharospasm: practice-oriented therapy with botulinum toxin employing reduced treatment intervals. *Ophthalmologe*. 2012;109(1):45-53. [Article in German.]
22. Jankovic J, Comella C, Hanschmann A, Grafe S. Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm-a randomized trial. *Mov Disord*. 2011;26(8):1521-1528.
23. Wabbels B, Reichel G, Fulford-Smith A, Wright N, Roggenkämper P. Double-blind, randomised, parallel group pilot study comparing two botulinum toxin type A products for the treatment of blepharospasm. *J Neural Transm*. 2011;118(2):233-239.
24. Dressler D. Routine use of Xeomin in patients previously treated with Botox: long term results. *Eur J Neurol*. 2009;16(suppl 2):2-5.

25. Jankovic J. Clinical efficacy and tolerability of Xeomin in the treatment of blepharospasm. *Eur J Neurol*. 2009;16(suppl 2):14-18.
26. Jankovic J, Kenney C, Grafe S, Goertelmeyer R, Comes G. Relationship between various clinical outcome assessments in patients with blepharospasm. *Mov Disord*. 2009;24(3):407-413.
27. Jost WH. Efficacy and safety of botulinum toxin type A free of complexing proteins (Xeomin) in cervical dystonia and blepharospasm. *Fut Neurol*. 2007;2:485-493.
28. Roggenkämper P, Jost W, Bihari K, Comes G, Grafe S; NT 201 Blepharospasm Study Team. Efficacy and safety of a new botulinum toxin type A free of complexing proteins in the treatment of blepharospasm. *J Neural Transm*. 2006;113(3):303-312.

## Cervical Dystonia

1. Gilman Kuric T, Popovic Z, Matosa S, et al. Memory-guided saccades and non-motor symptoms improve after botulinum toxin therapy in cervical dystonia. *J Clin Med*. 2024;13(19):5708.
2. Castagna A, Jinnah HA, Albanese A. Duration of botulinum toxin efficacy in cervical dystonia clinical trials: A scoping review. *Parkinsonism Relat Disord*. 2024;125:107011.
3. Hast MA, Kong AM, Desai S, Back S, Syed S, Holmes J. Patient characteristics and real-world use of botulinum toxins for the treatment of cervical dystonia, blepharospasm, and hemifacial spasm. *Toxins (Basel)*. 2024;16(8):362.
4. Albanese A, Bhatia KP, Cardoso F, et al. Isolated cervical dystonia: diagnosis and classification. *Mov Disord*. 2023;38(8):1367-1378.
5. Albanese A, Wissel J, Jost, WH, et al. Pain reduction in cervical dystonia following treatment with incobotulinumtoxinA: a pooled analysis. *Toxins (Basel)*. 2023;15(5):333.
6. Hefter H, Samadzadeh S. Exploring the interplay between the clinical and presumed effect of botulinum injections for cervical dystonia: a pilot study. *Toxins (Basel)*. 2023;15(10):592.
7. Hefter H, Schomaecker I, Schomaecker M, et al. Lessons about botulinum toxin A therapy from cervical dystonia patients drawing the course of disease: a pilot study. *Toxins (Basel)*. 2023;15(7):431.
8. Petracca M, Lo Monaco MR, Ialongo T, et al. Efficacy and safety of long-term botulinum toxin treatment for acquired cervical dystonia: a 25-year follow-up. *J Neurol*. 2023;270(1):340-347.
9. Comella C, Hauser RA, Isaacson SH, et al. Efficacy and safety of two incobotulinumtoxinA injection intervals in cervical dystonia subjects with inadequate benefit from standard injection intervals of botulinum toxin: Phase 4, open-label, randomized, noninferiority study. *Clin Park Relat Disord*. 2022;6:100142.
10. Hefter H, Ürer B, Brauns R, et al. Significant long-lasting improvement after switch to incobotulinum toxin in cervical dystonia patients with secondary treatment failure. *Toxins (Basel)*. 2022;14(1):44.
11. Hefter H, Ürer B, Brauns R, et al. The complex relationship between antibody titers and clinical outcome in botulinum toxin type A long-term treated patients with cervical dystonia. *J Neurol*. 2022;269(11):5991-6002.
12. Kreisler A, Djelad S, Simonin C, et al. Does ultrasound-guidance improve the outcome of botulinum toxin injections in cervical dystonia? *Rev Neurol (Paris)*. 2022;178(6):591-602.

13. Leplow B, Pohl J, Wöllner J, Weise D. Individual response to botulinum toxin therapy in movement disorders: a time series analysis approach. *Toxins (Basel)*. 2022;14(8):508.
14. Hefter H, Hartmann CJ, Kahlen U, Samadzadeh S, Rosenthal D, Moll M. Clinical improvement after treatment with incobotulinumtoxinA (XEOMIN®) in subjects with cervical dystonia resistant to botulinum toxin preparations containing complexing proteins. *Front Neurol*. 2021;12:636590.
15. Blood AJ, Kuster JK, Waugh JL, et al. White matter changes in cervical dystonia relate to clinical effectiveness of botulinum toxin treatment. *Front Neurol*. 2019;10:265.
16. Hu W, Rundle-Gonzalez V, Kulkarni SJ, et al. A randomized study of botulinum toxin versus botulinum toxin plus physical therapy for treatment of cervical dystonia. *Parkinsonism Relat Disord*. 2019;63:195-198.
17. Jankovic J, Truong D, Patel AT, et al. Injectable daxibotulinumtoxinA in cervical dystonia: A phase 2 dose-escalation multicenter study. *Mov Disord Clin Pract*. 2018;5(3):273-282.
18. Yi YG, Kim K, Yi Y, Choi YA, Leigh JH, Bang MS. Botulinum toxin type A injection for cervical dystonia in adults with dyskinetic cerebral palsy. *Toxins (Basel)*. 2018;10(5):203.
19. Dressler D, Saberi F. Safety of botulinum toxin short interval therapy using incobotulinumtoxinA. *J Neural Transm (Vienna)*. 2017;124(4):437-440.
20. Hefter H, Rosenthal D, Moll M. High Botulinum toxin neutralizing antibody prevalence under long-term cervical dystonia treatment. *Mov Disord Clin Pract*. 2016;3(5):500-550.
21. Dressler D, Tacik P, Adib Saberi F. Botulinum toxin therapy of cervical dystonia: duration of therapeutic effects. *J Neural Transm*. 2015;122(2):297-300.
22. Dressler D, Adib Saberi F, Kollewe K, Schrader C. Safety aspects of incobotulinumtoxinA high-dose therapy. *J Neural Transm*. 2014;122(2):327-333.
23. Dressler D, Kupsch A, Seitzinger A, Paus S. The dystonia discomfort scale (DDS): a novel instrument to monitor the temporal profile of botulinum toxin therapy in cervical dystonia. *Eur J Neurol*. 2014;21(3):459-462.
24. Evidente VG, Truong D, Jankovic J, Comella CL, Grafe S, Hanschmann A. IncobotulinumtoxinA (Xeomin®) injected for blepharospasm or cervical dystonia according to patient needs is well tolerated. *J Neurol Sci*. 2014;346(1-2):116-120.
25. Benecke R, Hauschke D. IncobotulinumtoxinA demonstrated equivalent efficacy to onabotulinumtoxinA in the treatment of cervical dystonia. *Botulinum J*. 2013;2(3/4):217.
26. Dressler D, Paus S, Seitzinger A, Gebhardt B, Kupsch A. Long-term efficacy and safety of incobotulinumtoxinA injections in patients with cervical dystonia. *J Neurol Neurosurg Psychiatry*. 2013;84(9):1014-1019.
27. Evidente V, Fernandez H, LeDoux M, et al. A randomized, double-blind study of repeated incobotulinumtoxinA (Xeomin®) in cervical dystonia. *J Neural Transm (Vienna)*. 2013;120(12):1699-1707.
28. Fernandez HH, Pagan F, Danisi F, et al. Prospective study evaluating incobotulinumtoxinA for cervical dystonia or blepharospasm: interim results from the first 145 subjects with cervical dystonia. *Tremor Other Hyperkinet Mov (N Y)*. 2013;3:tre-03-139-2924-1.
29. Fernandez HH, Pappert EJ, Comella CL, et al. Efficacy and safety of incobotulinumtoxinA in subjects previously treated with botulinum toxin versus toxin-naïve subjects with cervical dystonia. *Tremor Other Hyperkinet Mov (N Y)*. 2013;3:tre-03-140-2921-1.

30. Sethi K, Rodriguez R, Olayinka B. Erratum: Satisfaction with botulinum toxin treatment: a cross-sectional survey of patients with cervical dystonia. *J Med Econ*. 2013;16(2):327.
31. Jimenez-Shahed J. A new treatment for focal dystonias: incobotulinumtoxinA (Xeomin), a botulinum neurotoxin type A free from complexing proteins. *Neuropsychiatr Dis Treat*. 2012;8:13-25.
32. Pagan F, Harrison A. A guide to dosing in the treatment of cervical dystonia and blepharospasm with Xeomin: a new botulinum neurotoxin A. *Parkinsonism Relat Disord*. 2012;18:441-445.
33. Sethi K, Rodriguez R, Olayinka B. Satisfaction with botulinum toxin treatment: a cross-sectional survey of patients with cervical dystonia. *J Med Econ*. 2012;15(3):419-423.
34. Comella CL, Jankovic J, Truong DD, Hanschmann A, Grafe S. Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin, botulinumtoxin Type A, without accessory proteins) in patients with cervical dystonia. *J Neurol Sci*. 2011;308(1-2):103-109.
35. Dressler D. Routine use of Xeomin in patients previously treated with Botox: long term results. *Eur J Neurol*. 2009;16(suppl 2):2-5.
36. Santamato A, Panza F, Solfrizzi V, et al. Botulinum toxin type A in the treatment of focal hand dystonia after surgical treatment for thumb duplication. *Orthopedics*. 2009;32(7):529.
37. Jost W, Blümel J, Grafe S. Botulinum neurotoxin type A free of complexing proteins (XEOMIN) in focal dystonia. *Drugs*. 2007;67(5):669-683.
38. Jost WH. Efficacy and safety of botulinum toxin type A free of complexing proteins (Xeomin) in cervical dystonia and blepharospasm. *Fut Neurol*. 2007;2:485-493.
39. Benecke R, Jost WH, Kanovsky P, Ruzicka E, Comes G, Grafe S. A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. *Neurology*. 2005; 64(11):1949-1951.

## Chronic Sialorrhea

1. Hast MA, Kong AM, Abdelhadi J, Shah R, Szendrey A, Holmes J. Real-world observational analysis of clinical characteristics and treatment patterns of patients with chronic sialorrhea. *Toxins (Basel)*. 2024;16(8):366.
2. Bergmans B, Clark V, Isaacson SH, Bäumer T. Recommendations for a paradigm shift in approach to increase the recognition and treatment of sialorrhea in Parkinson's disease. *Clin Park Relat Disord*. 2023;9:100223.
3. Jost WH, Bäumer T, Bevot A, et al. Botulinum neurotoxin type A in the interdisciplinary treatment of sialorrhea in adults and children-update and practice recommendations. *Front Neurol*. 2023;14:1275807.
4. Tamadonfar ET, Lew MF. BoNT clinical trial update: sialorrhea. *Toxicon*. 2023;226:107087.
5. Berweck S, Banach M, Gaebler-Spira D, et al. Safety profile and lack of immunogenicity of incobotulinumtoxinA in pediatric spasticity and sialorrhea: a pooled analysis. *Toxins (Basel)*. 2022;14(9):585.
6. Toulemonde P, Maltezeanu A, Broucsault H, Fayoux P. Tolerance of salivary gland botulinum toxin A injection under local anesthesia for the treatment of sialorrhea in children: an observational study. *Eur Ann Otorhinolaryngol Head Neck Dis*. 2022;139(2):77-81.

7. Vova JA, Green MM, Brandenburg JE, et al. A consensus statement on the use of botulinum toxin in pediatric patients. *PM R*. 2022;14(9):1116-1142.
8. Berweck S, Bonikowski M, Heakyung K, et al. Placebo-controlled clinical trial of incobotulinumtoxinA for sialorrhea in children. SIPEXI. *Neurology*. 2021;97(14):e1425-e1436.
9. Jost WH, Steffen A, Berweck S. A critical review of incobotulinumtoxinA in the treatment of chronic sialorrhea in pediatric patients. *Expert Rev Neurother*. 2021;21(10):1059-1068.
10. Jost WH, Friedman A, Michel O, et al. Long-term incobotulinumtoxinA treatment for chronic sialorrhea: efficacy and safety over 64 weeks. *Parkinsonism Relat Disord*. 2020;70:23-30.
11. Bernardo P, Raiano E, Cappuccio G, et al. The treatment of hypersalivation in Rett Syndrome with botulinum toxin: efficacy and clinical implications. *Neurol Ther*. 2019;8(1):155-160.
12. Garuti G, Rao F, Ribuffo V, Sansone VA. Sialorrhea in patients with ALS: current treatment options. *Degener Neurol Neuromuscul Dis*. 2019;9:19-26.
13. Jost WH, Friedman A, Michel O, et al. SIAXI: Placebo-controlled, randomized, double-blind study of incobotulinumtoxinA for sialorrhea. *Neurology*. 2019;92(17):e1982-e1991.
14. Morgante F, Bavikatte G, Anwar F, Mohamed B. The burden of sialorrhoea in chronic neurological conditions: current treatment options and the role of incobotulinumtoxinA (Xeomin®). *Ther Adv Neurol Disord*. 2019;12:1756286419888601.
15. Paracka L, Kollwe K, Klietz M, Petri S, Dressler D. IncobotulinumtoxinA for hypersalivation in patients with amyotrophic lateral sclerosis: an open-label single-centre study. *J Neural Transm (Vienna)*. 2019;126(10):1341-1345.
16. Schwalje AT, Hoffman HT. Intraductal salivary gland infusion with botulinum toxin. *Laryngoscope Investig Otolaryngol*. 2019;4(5):520-525.
17. Taib BG, Williams SP, Sood S, Ung K, Nixon PP, Sharma R. Treatment of sialorrhoea with repeated ultrasound-guided injections of botulinum toxin A into the parotid and submandibular glands. *Br J Oral Maxillofac Surg*. 2019;57(5):442-448.
18. Martínez-Poles J, Nedkova-Hristova V, Escribano-Paredes J, et al. IncobotulinumtoxinA for sialorrhea in neurological disorders: a real-life experience. *Toxins (Basel)*. 2018;10(6):217.
19. Marvulli R, Gallo GA, Mastromauro L, et al. Efficacy and non invasive treatment of sialorrhea in Goldenhar Syndrome. *Endocr Metab Immune Disord Drug Targets*. 2018;18(4):397-400.
20. Restivo D, Panebianco M, Casabona A, et al. Botulinum toxin A for sialorrhea associated with neurological disorders: evaluation of the relationship between effect of treatment and the number of glands treated. *Toxins (Basel)*. 2018;10(2):55.
21. Marvulli R, Mastromauro L, De Venuto G, et al. Efficacy of incobotulinumtoxin type A (Xeomin) in the management of sialorrhea in neurodegenerative diseases. *J Alzheimers Dis Parkinsonism*. 2017;7:356.
22. Narayanaswamia P, Geisbusha T, Tarullia A, et al. Drooling in Parkinson's disease: a randomized controlled trial of incobotulinum toxin A and meta-analysis of botulinum toxins. *Parkinsonism Relat Disord*. 2016;30:73-77.
23. Dressler D. Routine use of Xeomin in patients previously treated with Botox: long term results. *Eur J Neurol*. 2009;16(suppl 2):2-5.

24. Bothwell JE, Clarke K, Dooley JM, et al. Botulinum toxin A as a treatment for excessive drooling in children. *Pediatr Neurol*. 2002;27:18-22.

### Genitourinary

1. Kavcic N, Avsenak A, Zmazek J, Serdinsek T, But I. Efficacy and safety of intradetrusor abobotulinumtoxinA and incobotulinumtoxinA in women with overactive bladder and the value of local anesthesia: a randomized clinical study. *Wien Klin Wochenschr*. Published online August 23, 2024.
2. Giannantoni A, Gubbiotti M, Rubliotta E, et al. IncobotulinumtoxinA versus onabotulinumtoxinA intradetrusor injections in patients with neurogenic detrusor overactivity incontinence: a double-blind, randomized, non-inferiority trial. *Minerva Urol Nephrol*. 2022;74(5):625-635.
3. Grishin A, Spaska A, Kayumova L. Correction of overactive bladder with botulinum toxin type A (BTX-A). *Toxicon*. 2021;200:96-101.
4. Hampel C, D'Andrea D, Gillitzer R, et al. Comparison of two different Botulinumtoxin A products (Xeomin, Botox) used for detrusor injection in patients with bladder overactivity (BO)—a prospective randomized double-blind study. *Eur Urol Suppl*. 2012;1(11):e463-e463a.
5. Asafu-Adjei D, Small A, McWilliams G, Galea G, Chung D, Pak J. The intravesical injection of highly purified botulinum toxin for the treatment of neurogenic detrusor overactivity. *Can Urol Assoc J*. 2020;14(10):E520-E526.
6. Proietti S, Giovannozzi S, Lepri E, Lepri L, Gubbiotti M, Giannantoni A. Clinical and urodynamic efficacy of Xeomin in the treatment of neurogenic detrusor overactivity: preliminary results. *Neurol Urodyn*. 2011;30(suppl):45-46.
7. Conte A, Giannantoni A, Gubbiotti M, et al. Intradetrusorial botulinum toxin in patients with multiple sclerosis: a neurophysiological study. *Toxins (Basel)*. 2015;7(9):3424-3435.

### Hemifacial Spasm

1. Hast MA, Kong AM, Desai S, Back S, Syed S, Holmes J. Patient characteristics and real-world use of botulinum toxins for the treatment of cervical dystonia, blepharospasm, and hemifacial spasm. *Toxins (Basel)*. 2024;16(8):362.
2. Wenninger FC, Wabbels B. Frequency of hemorrhagic side effects of botulinum neurotoxin treatment in patients with blepharospasm and hemifacial spasm on antithrombotic medication. *Toxins (Basel)*. 2022;14(11):769.
3. Bladen JC, Favor M, Litwin A, Malhotra R. Switchover study of onabotulinumtoxinA to incobotulinumtoxinA for facial dystonia. *Clin Exp Ophthalmol*. 2020;48:1146-1151.
4. Dressler D. Routine use of Xeomin in patients previously treated with Botox: long term results. *Eur J Neurol*. 2009;16(suppl 2):2-5.

### Hyperhidrosis

1. Elshabory O, Mohamed HAK, Zaky M, Elsaie ML. Comparative study between fractional laser assisted drug delivery of botulinum toxin versus botulinum toxin injection in primary palmar and axillary hyperhidrosis. *Arch Dermatol Res*. 2025;317(1):241.

2. Prodan-Barbulescu C, Castiglione L, Burtic SR, et al. Longitudinal assessment of facial hyperhidrosis management: evaluating the utility and quality of life improvements following botulinum toxin injection. *Toxins (Basel)*. 2024;16(1):59.
3. Campanati A, Martina E, Gregoriou S, et al. Botulinum toxin type A for treatment of forehead hyperhidrosis: multicenter clinical experience and review from literature. *Toxins (Basel)*. 2022;14(6):372.
4. Trindade de Almeida AR, Noriega LF, Bechelli L, Suárez MV. Randomized controlled trial comparing the efficacy and safety of two injection techniques of incobotulinumtoxinA for axillary hyperhidrosis. *J Drugs Dermatol*. 2020;19(7):765-770.
5. da Costa A, Pereira ESP, de Oliveira Pereira M, et al. Six-month comparative analysis monitoring the progression of the largest diameter of the sweating inhibition halo of different botulinum toxins type-A. *Aesthet Surg J*. 2019;39(9):993-1004.
6. Wu CJ, Chang CK, Wang CY, Liao YS, Chen SG. Efficacy and safety of botulinum toxin A in axillary bromhidrosis and associated histological changes in sweat glands: a prospective randomized double-blind side-by-side comparison clinical study. *Dermatol Surg*. 2019;45(12):1605-1609.
7. Campanati A, Giuliodori K, Martina E, Giuliano A, Ganzetti G, Offidani A. Onabotulinumtoxin type A (Botox) versus Incobotulinumtoxin type A (Xeomin) in the treatment of focal idiopathic palmar hyperhidrosis: results of a comparative double-blind clinical trial. *J Neural Transm*. (Vienna). 2014;121(1):21-26.
8. Rosell K, Hymnelius K, Swartling C. Botulinum toxin type A and B improve quality of life in patients with axillary and palmar hyperhidrosis. *Acta Derm Venereol*. 2013;93(3):335-339.
9. Dressler D. Comparing Botox and Xeomin for axillar hyperhidrosis. *J Neural Transm*. 2010;117(3):317-319.
10. Dressler D. Routine use of Xeomin in patients previously treated with Botox: long term results. *Eur J Neurol*. 2009;16(suppl 2):2-5.

## Migraine

1. Lucchese S, Daripa B, Pulimamidi S. A Retrospective comparison of onabotulinum toxin A and incobotulinum toxin A in terms of efficacy, tolerability, duration of effect, and pain on injection administration site for the treatment of chronic migraine. *Cureus*. 2024;16(2):e53969.
2. Hemasian H, Abedini F, Arab A, Khorvash F. A novel technique of botulinum toxin injection around skull sutures for chronic migraine: A randomized controlled clinical trial. *J Res Med Sci*. 2022;27:85.
3. Ion I, Renard D, Le Floch A, et al. Monocentric prospective study into the sustained effect the sustained effect of incobotulinumtoxinA (XEOMIN) botulinum toxin in chronic refractory migraine. *Toxins (Basel)*. 2018;10(6):221.
4. Kazerooni R, Lin J, Blake A, Lessig S. IncobotulinumtoxinA for migraine: a retrospective case series. *Clin Ther*. 2015;37(8):1860-1864.
5. Salazar G, Fragoso M, Rey A, Sánchez L, Navarro MG. IncobotulinumtoxinA (Xeomin) and onabotulinumtoxinA (Botox) for chronic migraine headache: experience with higher doses and changes to the injection technique. *J Neurol Disord*. 2014;2(6):192-196.

6. Lee JH, Park JH, Lee SK, et al. The efficacy and safety of incobotulinum toxin A in periocular rhytides and masseteric hypertrophy: side by side comparison with onabotulinum toxin A. *J Dermatolog Treat.* 2014;25(4):326-330.

### **Ophthalmology Uses Other than Benign Essential Blepharospasm**

1. Hunt SV, Schulz CB, Malhotra R. Evaluating the effectiveness of lacrimal gland botulinum toxin using the TEARS score. *Ophthalmic Plast Reconstr Surg.* 2024;40(2):192-197.
2. Vokurka Topljak S, Galiot Delić M, Mandić K, Perić S, Baretić M, Juri Mandić J. Nonsurgical treatment for upper eyelid retraction in patients with inactive Graves' orbitopathy. *Int Ophthalmol.* 2023;43(7):2291-2299.
3. Hess K, Schmitt M, Wabbels B. Periorbital injections of botulinum toxin a: a novel therapeutic option for convergence spasm in neuropsychiatric disorders. *J Neurol.* 2022;269(1):243-250.
4. Maroto Rodríguez B, Stoica BTL, Toledano Fernández N, Genol Saavedra I. Treatment for functional epiphora with botulinum toxin-A versus lateral tarsal strip in a randomized trial. *Arch Soc Esp Oftalmol (Engl Ed).* 2022;97(10):549-557.
5. Alsuhaibani AH, Eid SA. Botulinum toxin injection and tear production. *Curr Opin Ophthalmol.* 2018;29(5):428-433.
6. Girard B, Piaton JM, Keller P, Nguyen TH. Botulinum neurotoxin A injection for the treatment of epiphora with patent lachrymal ducts. *J Fr Ophtalmol.* 2018;41(4):343-349.

### **Orthopedics and Rehabilitation Medicine**

1. Fishman L. Incobotulinumtoxin A and yoga-like isometric exercise in adolescent idiopathic lumbar scoliosis—a randomized pilot study. *Muscles.* 2024;3(1):28-39.
2. Galván Ruiz A, Vergara Díaz G, Rendón Fernández B, Echevarría Ruiz De Vargas C. Effects of ultrasound-guided administration of botulinum toxin (incobotulinumtoxinA) in patients with lateral epicondylitis. *Toxins (Basel).* 2019;11(1):46.
3. Cinone N, Letizia S, Santoro L, et al. Intra-articular injection of botulinum toxin type A for shoulder pain in glenohumeral osteoarthritis: a case series summary and review of the literature. *J Pain Res.* 2018;11:1239-1245.
4. Read F, Boyd R, Barber L. Longitudinal assessment of gait quality in children with bilateral cerebral palsy following repeated lower limb intramuscular botulinum toxin-A injections. *Res Dev Disabil.* 2017;68:35-41.
5. Pirali C, Santus G, Faletti S, De Grandis D. Botulinum toxin treatment for slipping rib syndrome: a case report. *Clin J Pain.* 2013;29(10):e1-3. Santus G, Faletti S, De Grandis D. Botulinum toxin treatment for slipping rib syndrome: a case report. *Clin J Pain.* 2013;29:e1-e3.
6. Castiglione A, Bagnato S, Boccagni C, Romano MC, Galardi G. Efficacy of intra-articular injection of botulinum toxin type a in refractory hemiplegic shoulder pain. *Arch Phys Med and Rehabil.* 2011;92(7):1034-1037.
7. Berto G, Marchi P, Lutzoni, L, Anasaloni L, Straudi S, Basaglia N. Robot-assisted therapy and botulinum type A: a promising approach for upper limb ataxia rehabilitation. *Gait and Posture.* 2011;33(suppl 1):S63.

8. Santamato A, Ranieri M, Panza F, et al. Botulinum toxin type A in the treatment of painful adductor muscle contracture after total hip arthroplasty. *Orthopedics*. 2009;32(10): orthosupersite.com/view.asp?rID=43784.

## Pain

1. Hefter H, Moll M, Samadzadeh S. Complete improvement of severe forearm complex regional pain syndrome with six high-dose incobotulinumtoxin A injections: clinical implications with respect to the literature. *Toxins (Basel)*. 2024;16(11):488.
2. Klee M, Hørmann Thomsen T, Enggaard TP, et al. Perineural injections of incobotulinumtoxin-A for diabetic neuropathic pain of the lower extremities: protocol for a phase II, single-centre, double-blind, randomised, placebo-controlled trial (the PINBOT study). *BMJ Open*. 2024;14(1):e074372.
3. Albanese A, Wissel J, Jost, WH, et al. Pain reduction in cervical dystonia following treatment with incobotulinumtoxinA: a pooled analysis. *Toxins (Basel)*. 2023;15(5):333.
4. Alizadeh R, Taheri M, Beiranvand S, Fereydoonia B. Evaluation of the effectiveness of botulinum toxin injection on reducing phantom pain in patients. *Interdiscip Neurosurg*. 2023; 32:101712.
5. Spagna A, Attal N. Botulinum toxin A and neuropathic pain: An update. *Toxicon*. 2023;232:107208.
6. Teuschl Y, Bancher C, Dachenhausen A, et al. Botulinum toxin-A for the treatment of neuropathic pain after decompressive craniotomy in stroke: two cases. *Case Rep Neurol*. 2023;15(1):192-198.
7. Villa-Muñoz P, Albaladejo-Belmonte M, Nohales-Alfonso FJ, Alberola-Rubio J, Garcia-Casado J. Treatment of vestibulodynia with submucosal injections of incobotulinumtoxinA into targeted painful points: an open-label exploratory study. *Toxins (Basel)*. 2023;15(8):476.
8. Charvin M, Orta C, Davy L, et al. Botulinum toxin A for chronic exertional compartment syndrome: a retrospective study of 16 upper- and lower-limb cases. *Clin J Sport Med*. 2022;32(4):e436-e440.
9. Ri S, Kivi A, Wissel J. The safety and effect of local botulinumtoxin A injections for long-term management of chronic pain in post-herpetic neuralgia: literature review and cases report treated with incobotulinumtoxin A. *J Pers Med*. 2021;11(8):758.
10. Albaladejo-Belmonte M, Nohales-Alfonso FJ, Tarazona-Motes M, De-Arriba M, Alberola-Rubio J, Garcia-Casado J. Effect of BoNT/A in the surface electromyographic characteristics of the pelvic floor muscles for the treatment of chronic pelvic pain. *Sensors (Basel)*. 2021;21(14):4668.
11. Baurant E, Franké O, Amiel C, et al. Treatment of acute dysmenorrhoea and pelvic pain syndrome of uterine origin with myometrial botulinum toxin injections under hysteroscopy: A pilot study. *J Gynecol Obstet Hum Reprod*. 2021;50(4):101972.
12. Levesque A, Ploteau S, Michel F, et al. Botulinum toxin infiltrations versus local anaesthetic infiltrations in pelvic floor myofascial pain: multicentre, randomized, double-blind study. *Ann Phys Rehabil Med*. 2021;64(1):101354.

13. Tarazona-Motes M, Albaladejo-Belmonte M, Nohales-Alfonso FJ, De-Arriba M, Garcia-Casado J, Alberola-Rubio J. Treatment of dyspareunia with botulinum neurotoxin type A: clinical improvement and influence of patients' characteristics. *Int J Environ Res Public Health*. 2021;18(16):8783.
14. Wissel J, Camões-Barbosa A, Comes G, Althaus M, Scheschonka A, Simpson DM. Pain reduction in adults with limb spasticity following treatment with incobotulinumtoxinA: a pooled analysis. *Toxins (Basel)*. 2021;13(12):887.
15. Cordero-Garcia C, Garcia-Delgado MM. Efficacy of ultrasound-guided injections of incobotulinumtoxinA in the management of piriformis muscle syndrome. *Ann Phys Rehabil Med*. 2018;61:e162.
16. Restivo DA, Casabona A, Frittitta L, et al. Efficacy of botulinum toxin A for treating cramps in diabetic neuropathy. *Ann Neurol*. 2018;84(5):674-682.
17. Rodríguez-Piñero M, Vidal Vargas V, Jiménez Sarmiento AS. Long-term efficacy of ultrasound-guided injection of incobotulinumtoxinA in piriformis syndrome. *Pain Med*. 2018;19(2):408-411.
18. Diener SA, Breimhorst M, Vogt T, et al. Differential effect of incobotulinumtoxin A on pain, neurogenic flare and hyperalgesia in human surrogate models of neurogenic pain. *Eur J Pain*. 2017;21(8):1326-1335.
19. Fishman L, Wilkins A, Rosner B. Electro physiologically identified piriformis syndrome is successfully treated with incobotulinumtoxinA and physical therapy. *Muscle and Nerve*. 2017;56:258-263.
20. Rostami R, Mittal SO, Radmand R, Jabbari B. Incobotulinum toxin-A improves post-surgical and post-radiation pain in cancer patients. *Toxins (Basel)*. 2016;8(1):22.
21. Baurant E, Quintas-Marquès L, Eggermont J, et al. Use of botulinum neurotoxin type A (Xeomin) injections to the perineal muscles in cases of perineal pain and dysfunction associated with pelvic floor muscle overcontraction and myalgia. *Toxicon*. 2015;(93):S7-S8.
22. Santamato A, Micello MF, Valeno G, et al. Ultrasound-guided injection of botulinum toxin type A for piriformis muscle syndrome: a case report and review of the literature. *Toxins (Basel)*. 2015;7(8):3045-3056.
23. Dressler D, Adib Saberi F. Botulinum toxin in myotonia congenita: it does not help against rigidity and pain. *J Neural Transm*. 2014;121(5):531-532.
24. Kleiner-Fisman G, Khoo E, Moncrieffe N, Forbell T, Gryfe P, Fisman D. A randomized, placebo-controlled pilot trial of botulinum toxin for paratonic rigidity in people with advanced cognitive impairment. *PLoS One*. 2014;23;9(12):e114733.

### **Parkinson's Disease Tremor and Essential Tremor**

1. Grippe T, Chen R. Botulinum toxin in the management of parkinsonian disorders. *Toxicon*. 2023;232:107209.
2. Lapostolle A, Houot M, Mongin M, Degos B. Comparison of botulinum neurotoxin efficiency in dystonia associated with Parkinson's disease and atypical parkinsonism: a retrospective study with a self-reported improvement scale. *J Neurol*. 2022;269(11):6021-6028.
3. Samotus O, Mahdi Y, Jog M. Real-world longitudinal experience of botulinum toxin therapy for Parkinson and essential tremor. *Toxins (Basel)*. 2022;14(8):557.

4. Samotus O, Lee J, Jog M. Developing a consistent, reproducible botulinum toxin type A dosing method for upper limb tremor by kinematic analysis. *Toxins (Basel)*. 2021;13(4):264.
5. Jog M, Lee J, Scheschonka A, et al. Tolerability and efficacy of customized incobotulinumtoxinA injections for essential tremor: a randomized, double-blind, placebo-controlled study. *Toxins (Basel)*. 2020;12(12):807.
6. Mittal SO, Jog M, Lee J, Jabbari B. Novel botulinum toxin injection protocols for Parkinson tremor and essential tremor - the yale technique and sensor-based kinematics procedure for safe and effective treatment. *Tremor Other Hyperkinet Mov (N Y)*. 2020;10:61.
7. Soh D, Fasano A. IncobotulinumtoxinA and deep brain stimulation. *Can J Neurol Sci*. 2019;46(5):603-606.
8. Jocson A, Lew M. Use of botulinum toxin in Parkinson's disease. *Parkinsonism Relat Disord*. 2019;59:57-64.
9. Samotus O, Lee J, Jog M. Personalized bilateral upper limb essential tremor therapy with botulinum toxin using kinematics. *Toxins (Basel)*. 2019;11(2):125.
10. Mittal SO, Machado D, Richardson D, Dubey D, Jabbari B. Botulinum toxin in essential hand tremor- a randomized double-blind placebo-controlled study with customized injection approach. *Parkinsonism Relat Disord*. 2018;56:65-69.
11. Samotus O, Lee J, Jog M. Long-term tremor therapy for Parkinson and essential tremor with sensor-guided botulinum toxin type A injections. *PLoS One*. 2017;12(6):e0178670.
12. Mittal SO, Machado D, Richardson D, Dubey D, Jabbari B. Botulinum toxin in Parkinson disease tremor: a randomized, double-blind, placebo-controlled study with a customized injection approach. *Mayo Clin Proc*. 2017;92(9):1359-1367.
13. Slawek J, Madalinski M. Botulinum toxin therapy for nonmotor aspects of Parkinson's disease. *Int Rev Neurobiol*. 2017;134:1111-1142.
14. Samotus O, Rahimi F, Lee J, Jog M. Functional ability improved in essential tremor by incobotulinumtoxinA injections using kinematically determined biomechanical patterns - new future. *PLoS One*. 2016;11(4):e0153739.
15. Rahimi F, Samotus O, Lee J, Jog M. Effective management of upper limb parkinsonian tremor by incobotulinumtoxinA injections using sensor-based biomechanical patterns. *Tremor Other Hyperkinet Mov (N Y)*. 2015;5:348.
16. Tassorelli C, De Icco R, Alfonsi E, et al. Botulinum toxin type A potentiates the effect of neuromotor rehabilitation of Pisa syndrome in Parkinson disease: a placebo-controlled study. *Parkinsonism Relat Disord*. 2014;20(11):1140-1144.
17. Rahimi F, Bee C, Debicki D, Roberts AC, Bapat P, Jog M. Effectiveness of BoNT A in Parkinson's disease upper limb tremor management. *CA J Neurol Sci*. 2013;40(5):663-669.

### **Pediatric Spasticity**

1. Marvulli R, Lagioia G, Ianieri G, et al. Intrathecal baclofen infusion-botulinum toxin combined treatment efficacy in the management of spasticity due to cerebral palsy. *CNS Neurol Disord Drug Targets*. 2024;23(7):917-926.
2. Bonfert M, Heinen F, Kaňovský P, et al. Spasticity-related pain in children/adolescents with cerebral palsy. Part 2 IncobotulinumtoxinA efficacy results from a pooled analysis. *J Pediatr Rehabil Med*. 2023;16(1):83-98.

3. Murgia M, de Sire A, Ruiu P, et al. Botulinum toxin type A for spasticity in cerebral palsy patients: Which impact on popliteal angle to hamstring length? A proof-of-concept study. *J Back Musculoskelet Rehabil.* 2023;36(5):1193-1201.
4. Berweck S, Banach M, Gaebler-Spira D, et al. Safety profile and lack of immunogenicity of incobotulinumtoxinA in pediatric spasticity and sialorrhea: a pooled analysis. *Toxins (Basel).* 2022;14(9):585.
5. Erratum to: IncobotulinumtoxinA for the treatment of lower-limb spasticity in children and adolescents with cerebral palsy: A phase 3 study. *J Pediatr Rehabil Med.* 2022;15(2):407-409.
6. Heinen F, Bonfert M, Kaňovský P, et al. Spasticity-related pain in children/adolescents with cerebral palsy. Part 1: Prevalence and clinical characteristics from a pooled analysis. *J Pediatr Rehabil Med.* 2022;15(1):129-143.
7. Kaňovský P, Heinen F, Schroeder AS, et al. Safety and efficacy of repeat long-term incobotulinumtoxinA treatment for lower limb or combined upper/lower limb spasticity in children with cerebral palsy. *J Pediatr Rehabil Med.* 2022;15(1):113-127.
8. Vova JA, Green MM, Brandenburg JE, et al. A consensus statement on the use of botulinum toxin in pediatric patients. *PM R.* 2022;14(9):1116-1142.
9. Bonikowski M, Sławek J. Safety and efficacy of botulinum toxin type A preparations in cerebral palsy - an evidence-based review. *Neurol Neurochir Pol.* 2021;55(2):158-164.
10. Dabrowski E, Chambers HG, Gaebler-Spira D, et al. IncobotulinumtoxinA efficacy / safety in upper-limb spasticity in pediatric cerebral palsy: randomized controlled trial. *Pediatr Neurol.* 2021;123:10-20.
11. Heinen F, Kaňovský P, Schroeder AS, et al. IncobotulinumtoxinA for the treatment of lower-limb spasticity in children and adolescents with cerebral palsy: a phase 3 study. *J Pediatr Rehabil Med.* 2021;14(2):183-197.
12. Kim H, Kolaski K. Is botulinum toxin type A more effective and safer than other treatments for the management of lower limb spasticity in children with cerebral palsy? A Cochrane Review summary with commentary. *NeuroRehabilitation.* 2021;49(1):161-164.
13. Farag S, Mohammed M, Sobky T, Kadery N, Zohiery A. Botulinum toxin A injection in treatment of upper limb spasticity in children with cerebral palsy. *JBSJ Reviews.* 2020;8(3):e0119.
14. León-Valenzuela A, Palacios JS, Del Pino Algarrada R. IncobotulinumtoxinA for the treatment of spasticity in children with cerebral palsy - a retrospective case series focusing on dosing and tolerability. *BMC Neurol.* 2020;20(1):126.
15. Kelly B, MacKay-Lyons M, Berryman S, Hyndman J, Wood E. Casting protocols following BoNT-A injections to treat spastic hypertonia of the triceps surae in children with cerebral palsy and equinus gait: a randomized controlled trial. *Phys Occup Ther Pediatr.* 2019;39(1):77-93.
16. Paulson A, Zigler CK, Houtrow A, Pruitt D, Botulinum toxin: techniques within pediatric physiatry. *PM&R.* 2019;11(1):38-44.
17. Bourseul J, Molina A, Lintanf M, et al. Early botulinum toxin injections in infants with musculoskeletal disorders: a systematic review of safety and effectiveness. *Arch Phys Med Rehabil.* 2018;99(6):1160-1176.e5.

18. Kawano A, Yanagizono T, Kadouchi I, Umezaki T, Chosa E. Ultrasonographic evaluation of changes in the muscle architecture of the gastrocnemius with botulinum toxin treatment for lower extremity spasticity in children with cerebral palsy. *J Orthop Sci.* 2018;23(2):389-393.
19. Do HK, Jo, GY, Kwon JK, Kim WJ. Botulinum Toxin-A injection in the treatment of spasticity in a infantile-onset neurodegeneration with brain iron accumulation: a case report. *Ann Rehab Med.* 2018;42(2):363-367.
20. Lin CI, Chen KL, Kuan TS, Lin SH, Lin WP, Lin YC. Botulinum toxin injection to improve functional independence and to alleviate parenting stress in a child with advanced pantothenate kinase-associated neurodegeneration: a case report and literature review. *Medicine (Baltimore).* 2018;97(20):e10709.
21. Hong BY, Chang HJ, Lee SJ, Lee S, Park JH, Kwon JY. Efficacy of repeated botulinum toxin type A injections for spastic equinus in children with cerebral palsy-a secondary analysis of the randomized clinical trial. *Toxins (Basel).* 2017;9(8):253.
22. Kurenkov AL, Klochkova OA, Bursagova BI, et al. [Efficacy and safety of botulinum toxin type A (IncobotulinumtoxinA) in the treatment of patients with cerebral palsy]. *Zh Nevrol Psikhiatr Im S Korsakova.* 2017;117(11):37-44. [Article in Russian]
23. Read F, Boyd R, Barber L. Longitudinal assessment of gait quality in children with bilateral cerebral palsy following repeated lower limb intramuscular botulinum toxin-A injections. *Res Dev Disabil.* 2017;68:35-41.
24. Carraro E, Trevisi E, Martinuzzi A. Safety profile of incobotulinum toxin A [Xeomin®] in gastrocnemius muscles injections in children with cerebral palsy: randomized double-blind clinical trial. *Eur J Paediatr Neurol.* 2016; 20(4):532-537.
25. Geister T, Quintanar-Solares M, Martin M, Aufhammer S, Asmus F. Qualitative development of the 'Questionnaire on Pain caused by Spasticity (QPS),' a pediatric patient-reported outcome for spasticity-related pain in cerebral palsy. *Qual Life Res.* 2014;23(3):887-896.
26. Elkamil AI, Andersen GL, Skranes J, Lamvik T, Vik T. Botulinum neurotoxin treatment in children with cerebral palsy: a population-based study in Norway. *Eur J Paediatr Neurol.* 2012;16(5):522-527.
27. Moguel-Ancheita S, Valdés-Barrena A, Guadalupe Padilla-Sánchez F. Neurorrehabilitación visual de pacientes con daño cerebral usando toxina botulínica. *Cir Cir.* 2012; 80:320-326. [Article in Spanish]
28. Santamato A, Panza F, Ranieri M, Fiore P. Effect of botulinum toxin type A and modified constraint-induced movement therapy on motor function of upper limb in children with obstetrical brachial plexus palsy. *Childs Nerv Syst.* 2011;27:2187-2192.

### **Temporomandibular Joint Disorder (TMJ), Facial Pain, and/or Facial Palsy**

1. Martenot A, Devoti JF, Pons M, et al. Persistent myogenic temporomandibular disorders: Are navigation-guided botulinum toxin-A injections into the lateral pterygoid muscles effective? *J Stomatol Oral Maxillofac Surg.* 2024;125(5):101715.
2. Sitnikova V, Kämpfi A, Kämpfi L, et al. Clinical benefit of botulinum toxin for treatment of persistent TMD-related myofascial pain: A randomized, placebo-controlled, cross-over trial. *Pain Pract.* Published online July 4, 2024.

3. Ferreira EF, Camões-Barbosa A. IncobotulinumtoxinA in refractory temporomandibular disorder due to disk dislocation: a prospective study. *J Stomatol Oral Maxillofac Surg*. 2024;125(5S1):101804.
4. Ângelo DF, Sanz D, Cardoso HJ. Effectiveness of double-puncture temporomandibular joint arthrocentesis with viscosupplementation in different categories of severity - a prospective study. *J Craniomaxillofac Surg*. 2023;51(11):659-667.
5. Ângelo DF, Sanz D, Maffia F, Cardoso HJ. Outcomes of incobotulinumtoxinA injection on myalgia and arthralgia in patients undergoing temporomandibular joint arthroscopy: a randomized controlled trial. *Toxins (Basel)*. 2023;15(6):376.
6. Anwar H, Attard A, Green J, Elledge ROC. Botulinum toxin in the management of myalgia in temporomandibular disorders: are all injections equal? *Br J Oral Maxillofac Surg*. 2023;61(1):89-93.
7. Hosseini M, Asarzaghan F, Farhad S, Aligjanpour S. Trigeminal neuralgia: incobotulinumtoxinA (Xeomin), can it decrease the pharmacological intervention? (A case series). *Caspian J Intern Med*. 2023;14(2):376-379.
8. Sitnikova V, Kämppi A, Teronen O, Kempainen P. Effect of botulinum toxin injection on emg activity and bite force in masticatory muscle disorder: a randomized clinical trial. *Toxins (Basel)*. 2022;14(8):545.
9. Wojtecki L, Maierhofer O, Albrecht P. Intraoral alveolar submucosal injections of incobotulinumtoxin A: relief of therapy-refractory trigeminal neuropathy after tooth extraction. *eNeurologicalSci*. 2021;25:100376.
10. Akulov M, Orlova O, Orlova A, et al. IncobotulinumtoxinA treatment of facial nerve palsy after neurosurgery. *J Neurol Sci*. 2017;381:130-134.
11. Patel A, Lerner M, Blitzer A. IncobotulinumtoxinA injection for temporomandibular joint disorder: a randomized controlled pilot study. *Ann Otol Rhinol Laryngol*. 2017;126(4):328-333.
12. Garcia Moreno J, Pacheco Cortegana E, Abril-Jaramillo J. Temporomandibular disorders treated successfully with incobotulinumtoxinA. *Toxicon*. 2016;123(suppl):S64-S65.
13. Rutzen I, Atkins D, Motta K. EMG guided botulinum toxin type A injections for functional problems associated to congenital facial palsy: a case report. *PM R*. 2016;8(9S):S261-S262.
14. Krel R, Mednick T, Spinner W. A case series: incobotulinumtoxin A - a novel therapy for refractory trigeminal neuralgia. *Cephalalgia*. 2013;33(8):P152.
15. Santamato A, Panza F, Di Venere D, et al. Effectiveness of botulinum toxin type A treatment of neck pain related to nocturnal bruxism: a case report. *J Chiropr Med*. 2010;9:132-137.

### Other Conditions

1. Ranieri M, Riccardi M, Raele MV, et al. The synergistic effects of incobotulinum toxin and physiotherapy in a rare case of paraparesis in a 7-year-old affected by Klippel-Feil syndrome related to an *MYH3* gene mutation: a case report. *J Pers Med*. 2024;14(11):1073.
2. Calderón T, Arriero L, Cruz P, et al. Is chemodenervation with incobotulinumtoxinA an alternative to invasive chronic anal fissure treatments? *BMC Gastroenterol*. 2024;24(1):334.

3. Frucht SJ, George MC, Pantelyat A, et al. Incobotulinum toxin-A in professional musicians with focal task-specific dystonia: a double blind, placebo controlled, cross-over study. *Tremor Other Hyperkinet Mov (N Y)*. 2024;14:32.
4. Gu Y, Truong K, Kossard S, Lim A, Sebaratnam DF. Eccrine angiomatous hamartoma treated with multimodal vascular laser and incobotulinum. *Skin Health Dis*. 2024;4(5):e434.
5. Tereshko Y, Hector Ercole B, Christian L, et al. Botulinum toxin type A improves pain in numb chin syndrome. *Toxicon*. 2024;238:107565.
6. Canta R, Vestito L, Castellini P, et al. Successful treatment of post COVID-19 neurogenic dysphagia with botulinum toxin. *Eur J Case Rep Intern Med*. 2023;10(12):004105.
7. Díaz-Aristizabal U, Valdés-Vilches M, Fernández-Ferreras TR, et al. Effect of botulinum toxin type A in functionality, synkinesis and quality of life in peripheral facial palsy sequelae. *Neurologia (Engl Ed)*. 2023;38(8):560-565.
8. Fereydooni A, Ho VT, Olson EM, et al. Impact of scalene muscle botulinum toxin injection with and without surgery in neurogenic thoracic outlet syndrome. *Clin J Sport Med*. 2023;33(2):116-122.
9. Giuliano F, Denys P, Joussain C. Safety and effectiveness of repeated botulinum toxin a intracavernosal injections in men with erectile dysfunction unresponsive to approved pharmacological treatments: real-world observational data. *Toxins (Basel)*. 2023;15(6):382.
10. Krivda K, Clabeaux C, Yakopson V. Crocodile tear syndrome treated with lacrimal gland incobotulinum toxin A injection: a case series. *Digit J Ophthalmol*. 2023;29(4).
11. Ioannou CI, Hodde-Chriske FL, Altenmüller E. Long-term muscular atrophy and weakness following cessation of botulinum toxin type A injections in the flexor digitorum muscle of musicians with focal hand dystonia. *Toxins (Basel)*. 2023;15(4):296.
12. Lagos-Villaseca A, Bhatt NK, Abdolhosseini P, et al. Assessment of patients receiving short-interval botulinum toxin chemodenervation treatment for laryngeal dystonia and essential tremor of the vocal tract. *JAMA Otolaryngol Head Neck Surg*. 2023;149(7):615-620.
13. López-Juárez SE, Medina-Benítez A, Durán-Reyes R, Bagundo-Pérez BI, Fortuna-Sandoval OI, Trejo-García MS. Botulinum toxin A (IncobotulinumtoxinA) and pneumoperitoneum image-guided for hernia repair with loss of dominance. *Cir Cir*. 2023;91(1):117-121.
14. Filippetti M, Picelli A, Di Censo R, et al. IncobotulinumtoxinA injection for treating children with idiopathic toe walking: a retrospective efficacy and safety study. *Toxins (Basel)*. 2022;14(11):792.
15. Giuliano F, Denys P, Joussain C. Effectiveness and safety of intracavernosal incobotulinumtoxinA (Xeomin®) 100 U as an add-on therapy to standard pharmacological treatment for difficult-to-treat erectile dysfunction: a case series. *Toxins (Basel)*. 2022;14(4):286.
16. Goloktionov NA, Kashnikov VN, Tklich OV, et al. Comparison of different doses botulinum toxin type a efficacy in chronic anal fissure treatment. *Serb J Exp Clin Res*. 2022;23(1):13-28.
17. Kohli N, Lerner M, Rashty J, et al. IncobotulinumtoxinA (Xeomin) for the treatment of adductor laryngeal dystonia: a prospective, open-label clinical trial. *Am J Otolaryngol*. 2022;43(6):103613.

18. Martinez Del Carmen DT, Martí Mestre FX, Tripodi P, Macia Vidueira I, Ramos Izquierdo R, Romera Villegas A. Role of botulinum toxin in pectoralis minor syndrome. *Ann Vasc Surg.* 2022;81:225-231.
19. Mueller J, Langbein T, Mishra A, Baum RP. Safety of high-dose botulinum toxin injections for parotid and submandibular gland radioprotection. *Toxins (Basel).* 2022;14(1):64.
20. Sánchez-Torralvo FJ, Vázquez-Pedreño L, Gonzalo-Marín M, et al. Endoscopic intragastric injection of botulinum toxin a in obese patients accelerates weight loss after bariatric surgery: follow-up of a randomised controlled trial (IntraTox Study). *J Clin Med.* 2022;11(8):2126.
21. Fernández-Pajarín G, Martínez-Castrillo JC, Dominguez-Lorenzo JM, Vaamonde P. Invalidating hyoid dystonia: successful treatment with incobotulinumtoxinA. *Mov Disord Clin Pract.* 2021;8(2):264.
22. Frucht S, Nmashie A, George MC, et al. Double-blind, placebo-controlled, crossover study of incobotulinumtoxin-A in musician's focal hand dystonia. *Mov Disord.* 2021;36(suppl 1):S43.
23. Hefter H, Beek J, Rosenthal D, Samadzadeh S. Enhanced effect of botulinum toxin A injections into the extensor digitorum brevis muscle after local mechanical leg vibration: a case report. *Toxins (Basel).* 2021;13(6):423.
24. Hefter H, Samadzadeh S. Effective treatment of neurological symptoms with normal doses of botulinum neurotoxin in Wilson's disease: six cases and literature review. *Toxins (Basel).* 2021;13(4):241.
25. Miguel C, Cirera A. Retrospective study of the clinical effect of incobotulinumtoxinA for the management of myofascial pain syndrome in refractory patients. *Toxicon.* 2021;203:117-120.
26. Sánchez Torralvo FJ, Vázquez Pedreño L, Gonzalo Marín M, et al. Endoscopic intragastric injection of botulinum toxin A in obese patients on bariatric surgery waiting lists: a randomised double-blind study (IntraTox study). *Clin Nutr.* 2021;40(4):1834-1842.
27. Zakin E, Simpson DM. Botulinum Toxin Therapy in Writer's Cramp and Musician's Dystonia. *Toxins (Basel).* 2021;13(12):899.
28. Graillon N, Le Roux MK, Chossegros C, Haen P, Lutz JC, Foletti JM. Botulinum toxin for ductal stenosis and fistulas of the main salivary glands. *Int J Oral Maxillofac Surg.* 2019;48(11):1411-1414.
29. Park JE, Shamim EA, Panyakaew P, et al. Botulinum toxin and occupational therapy for Writer's cramp. *Toxicon.* 2019;169:12-17.
30. Costan VV, Dabija MG, Ciofu ML, Sulea D, Popescu E, Boisteanu O. A functional approach to posttraumatic salivary fistula treatment: the use of botulinum toxin. *J Craniofac Surg.* 2019;30(3):871-875.
31. Mittal SO, Machado D, Richardson D, Dubey D, Jabbari B. Botulinum toxin in restless legs syndrome-a randomized double-blind placebo-controlled crossover study. *Toxins (Basel).* 2018;10(10):401.
32. Basciani M, Intiso D. High dose of botulinum toxin type A (NT-201) for the treatment of dysphagia due to severe spasticity of upper oesophageal sphincter: A case report. *Clin Case Rep.* 2015;5:8.
33. Di Martino S, Dalise S, Lamola G, Venturi M, Rossi B, Chisari C. A beautician's dystonia: long-lasting effect of botulinum toxin. *Case Rep Neurol Med.* 2014;2014:686181.

34. Maari C, Marchessault P, Bissonnette R. Treatment of notalgia paresthetica with botulinum toxin A: a double-blind randomized controlled trial. *J Am Acad Dermatol*. 2014;70(6):1139-1141.
35. Castiglione A, Bagnato S, Boccagni C, Romano MC, Galardi G. Efficacy of intra-articular injection of botulinum toxin type A in refractory hemiplegic shoulder pain. *Arch Phys Med Rehabil*. 2011;92(7):1034-1037.

## **ADDITIONAL INFORMATION**

### **Flexible/Individualized Injection Scheme**

1. Comella C, Hauser RA, Isaacson SH, et al. Efficacy and safety of two incobotulinumtoxinA injection intervals in cervical dystonia subjects with inadequate benefit from standard injection intervals of botulinum toxin: Phase 4, open-label, randomized, noninferiority study. *Clin Park Relat Disord*. 2022;6:100142.
2. Evidente VG, Truong D, Jankovic J, Comella CL, Grafe S, Hanschmann A. IncobotulinumtoxinA (Xeomin®) injected for blepharospasm or cervical dystonia according to patient needs is well tolerated. *J Neurol Sci*. 2014;346(1-2):116-120.
3. Fezza J, Burns J, Woodward J, Truong D, Hedges T, Verma A. Blepharospasm patient survey: a structured interview evaluating botulinum toxin treatments. *Mov Disord*. 2014;29(suppl 1):S499.
4. Mori L, Trompetto C, Marinelli L, Canneva S, Colombano F, Abbruzzese G. Incobotulinum booster injections in patients with spasticity and dystonia after stroke. *Ann Phys Rehabil Med*. 2014;57:e48.
5. Evidente VG, Fernandez HH, LeDoux MS, et al. A randomized, double-blind study of repeated incobotulinumtoxinA (Xeomin®) in cervical dystonia. *J Neural Transm (Vienna)*. 2013;120(12):1699-1707.
6. Fernandez H, Evidente V, Truong D, Brodsky M. Long-term treatment of blepharospasm and cervical dystonia: incobotulinum toxin A is well tolerated when injected at flexible intervals based on patient's needs. *J Neurol Sci*. 2013;333(suppl 1):E120.
7. Truong DD, Gollomp SM, Jankovic J, et al. Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin®) injections in blepharospasm. *J Neural Transm*. 2013; 120(9):1345-1353.

### **Pharmacoeconomics**

1. Kazerooni R, Healy S, Verduzco-Gutierrez M. Disparities in access to spasticity chemodenervation specialists in the US: a retrospective cross-sectional study. *Am J Phys Med Rehabil*. 2024;103(3):203-207.
2. Hull M, Anupindi V, DeKoven M, et al. Botulinum toxin utilization, treatment patterns, and healthcare costs among patients with spasticity or cervical dystonia in the US. *Adv Ther*. 2023;40:3986-4003.
3. Kazerooni R, Howard I, Li X, Verduzco-Gutierrez M. Cost efficiency analysis for spasticity management based on physician botulinum toxin prescribing habits. *Arch Phys Med Rehabil*. 2022;103(6):1205-1209.

4. Hernández Herrero D, Miangolarra Page JC. Descriptive analysis of the annual cost of treating spasticity with different types of botulinum toxin A. *Neurologia (Engl Ed)*. 2022;37(8):653-660.
5. Kazerooni R, Howard IM, Keener AM, Bounthavong M. Real-world six-year national cost-minimization analysis of incobotulinumtoxinA and onabotulinumtoxinA in the VA/DoD healthcare systems. *Clinicoecon Outcomes Res*. 2021;13:603-609.
6. Kazerooni R, Watanabe JH. Comparison of botulinum toxins for treatment of movement disorders: real-world utilization and cost analysis in a national Medicare population. *J Manag Care Spec Pharm*. 2021;27(4):478-487.
7. Makino K, Mahant N, Tilden D, Aghajanian L. Cost-effectiveness of incobotulinumtoxinA in the treatment of sialorrhea in patients with various neurological conditions. *Neurol Ther*. 2020;9(1):117-133.
8. Turcu-Stiolica A, Subtirelu MS, Bumbea AM. Cost-utility analysis of incobotulinumtoxin-a compared with conventional therapy in the management of post-stroke spasticity in Romania. *Front Pharmacol*. 2020;10:1516.
9. Makino K, Tilden D, Guarnieri C, Mudge M, Baguley I. Cost effectiveness of long-term incobotulinumtoxinA treatment in the management of post-stroke spasticity of the upper limb from the Australian payer perspective. *Pharmacoecon Open*. 2019;3(1):93-102.
10. Sanz-Granda A, Marti MJ, Catalan MJ. Cost-utility analysis of two formulations of botulinum toxin type A in the treatment of blepharospasm and cervical dystonia in Spain. *Rev Neurol*. 2018;67(12):465-472. [Article in Spanish]
11. Dressler D, Bigalke H. Long-term stability of reconstituted incobotulinumtoxinA: how can we reduce costs of botulinum toxin therapy? *J Neur Trans*. 2017;124(10):1223-1225.
12. Rychlik R, Kreimendahl F, Schnur N, Lambert-Baumann J, Dressler D. Quality of life and costs of spasticity treatment in German stroke patients. *Health Economics Review*. 2016;(6):27.
13. Tilden D, Guarnieri C. Cost-effectiveness of incobotulinumtoxinA with flexible treatment intervals compared to onabotulinumtoxinA in the management of blepharospasm and cervical dystonia. *Value Health*. 2016;19(2):145-152.
14. Kazerooni R, Broadhead C. Cost-utility analysis of botulinum toxin type A products for the treatment of cervical dystonia. *Am J Health Syst Pharm*. 2015;72(4):301-307.
15. De Andrés-Nogales F, Morell A, Aracil J, Torres C, Oyagüez I, Casado MA. Cost analysis of the use of botulinum toxin type A in Spain. *Farm Hosp*. 2014;38(3):193-201. [Article in Spanish]
16. Zoons E, Dijkgraaf M, Dijk J, van Schaik I, Tijssen M. Botulinum toxin as treatment for focal dystonia: a systematic review of the pharmaco-therapeutic and pharmaco-economic value. *J Neurol*. 2012;259(12):2519-2526.
17. Chadda S, Tilden D, Jones D, Hawthorne M, Wolf T, Sykes D. Cost-effectiveness of Xeomin® in the management of cervical dystonia and blepharospasm. *Eur J Hosp Pharm Sci Pract*. 2009;15:38-46.

## Immunogenicity

1. Martin MU, Frevert J, Tay CM. Complexing protein-free botulinum neurotoxin A formulations: implications of excipients for immunogenicity. *Toxins (Base)*. 2024;16(2):101.

2. Dressler D, Rothwell JC, Bhatia K, et al. Botulinum toxin antibody titres: measurement, interpretation, and practical recommendations. *J Neurol*. 2023;270(3):1524-1530.
3. Hefter H, Rosenthal D, Samadzadeh S. "Pseudo"-secondary treatment failure explained via disease progression and effective botulinum toxin therapy: a pilot simulation study. *Toxins (Basel)*. 2023;15(10):618.
4. Hefter H, Brauns R, Ürer B, Rosenthal D, Albrecht P, Samadzadeh S. No secondary treatment failure during incobotulinumtoxin-A long-term treatment demonstrated by the drawing of disease severity. *Toxins (Basel)*. 2023;15(7):454.
5. Berweck S, Banach M, Gaebler-Spira D, et al. Safety profile and lack of immunogenicity of incobotulinumtoxinA in pediatric spasticity and sialorrhea: a pooled analysis. *Toxins (Basel)*. 2022;14(9):585.
6. Hefter H, Rosenthal D, Jansen A, et al. Significantly lower antigenicity of incobotulinumtoxin than abo- or onabotulinumtoxin. *J Neurol*. 2023;270(2):788-796.
7. Hefter H, Schomaecker I, Schomaecker M, Rosenthal D, Samadzadeh S. The use of high initial doses of botulinum toxin therapy for cervical dystonia is a risk factor for neutralizing antibody formation-a monocentric cross-sectional pilot study. *Medicina (Kaunas)*. 2022;58(1):88.
8. Hefter H, Ürer B, Brauns R, et al. Significant long-lasting improvement after switch to incobotulinum toxin in cervical dystonia patients with secondary treatment failure. *Toxins (Basel)*. 2022;14(1):44.
9. Hefter H, Ürer B, Brauns R, et al. The complex relationship between antibody titers and clinical outcome in botulinum toxin type A long-term treated patients with cervical dystonia. *J Neurol*. 2022;269(11):5991-6002.
10. Masakado Y, Dekundy A, Tateishi S, Kaji R. IncobotulinumtoxinA for post-stroke upper limb spasticity in neutralizing antibody-positive patients after botulinum toxin therapy: a report of two cases. *Prog Rehabil Med*. 2022;7:20220012.
11. Rahman E, Alhitmi HK, Mosahebi A. Immunogenicity to botulinum toxin type A: a systematic review with meta-analysis across therapeutic indications. *Aesthet Surg J*. 2022;42(1):106-120.
12. Car H, Bogucki A, Bonikowski M, et al. Botulinum toxin type-A preparations are not the same medications - basic science (Part 1). *Neurol Neurochir Pol*. 2021;55(2):133-140.
13. Carr WW, Jain N, Sublett JW. Immunogenicity of botulinum toxin formulations: potential therapeutic implications. *Adv Ther*. 2021;38(10):5046-5064.
14. Hefter H, Hartmann CJ, Kahlen U, Samadzadeh S, Rosenthal D, Moll M. Clinical improvement after treatment with incobotulinumtoxinA (XEOMIN®) in patients with cervical dystonia resistant to botulinum toxin preparations containing complexing proteins. *Front Neurol*. 2021;12:636590.
15. Tucker H, Osei-Poku F, Ashton D, et al. Management of Secondary Poor Response to Botulinum Toxin in Cervical Dystonia: A Multicenter Audit. *Mov Disord Clin Pract*. 2021;8(4):541-545.
16. Foster K, Beard M. Comments on immunogenicity associated with botulinum toxin treatment. *Toxins* 2019, 11, 491. *Toxins (Basel)*. 2020;12(2):71.

17. Hefter H, Brauns R, Ürer B, Rosenthal D, Albrecht P. Effective long-term treatment with incobotulinumtoxin (Xeomin®) without neutralizing antibody induction: a monocentric, cross-sectional study. *J Neurol*. 2020;267(5):1340-1347.
18. Park JY, Sunga O, Wanitphakdeedecha R, Frevert J. Neurotoxin impurities: a review of threats to efficacy. *Plast Reconstr Surg Glob Open*. 2020;8(1):e2627.
19. Samadzadeh S, Ürer B, Brauns R, et al. Clinical implications of difference in antigenicity of different botulinum neurotoxin type A preparations: clinical take-home messages from our research pool and literature. *Toxins*. 2020;12(8):499.
20. Walter U, Mühlenhoff C, Benecke R, et al. Frequency and risk factors of antibody-induced secondary failure of botulinum neurotoxin therapy. *Neurology*. 2020;94(20):e2109-e2120.
21. Bellows S, Jankovic J. Immunogenicity associated with botulinum toxin treatment. *Toxins*. 2019;11(9):E491.
22. Hefter H, Rosenthal D, Bigalke H, Moll M. Clinical relevance of neutralizing antibodies in botulinum toxin long-term treated still-responding patients with cervical dystonia. *Ther Adv Neurol Disord*. 2019;12.
23. Kerscher M, Wanitphakdeedecha R, Trindada de Almeida A, Maas C, Frevert J. IncobotulinumtoxinA: a highly purified and precisely manufactured botulinum neurotoxin type A. *J Drugs Dermatol*. 2019;18(1):52-57.
24. Albrecht P, Jansen A, Lee JI, et al. High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy. *Neurology*. 2019;92(1):e48-e54.
25. Dressler D, Pan L, Adib Saberi F. Antibody-induced failure of botulinum toxin therapy: re-start with low-antigenicity drugs offers a new treatment opportunity. *J Neural Transm (Vienna)*. 2018;125(10):1481-1486.
26. Fabbri M, Leodori G, Fernandes RM et al. Neutralizing antibody and botulinum toxin therapy: a systematic review and meta-analysis. *Neurotox Res*. 2016;29(1):105-117.
27. Hefter H, Rosenthal D, Moll M. High botulinum toxin-neutralizing antibody prevalence under long-term cervical dystonia treatment. *Mov Disord Clin Pract*. 2016;3(5):500-506.
28. Frevert J. Pharmaceutical, biological, and clinical properties of botulinum neurotoxin type A products. *Drugs R D*. 2015;15:1-9.
29. Ricciardi L, Ialongo T, Guidubaldi A, Di Giacopo R, Bentivoglio A. Blepharospasm with non-satisfactory response to treatment: our experience with incobotulinumtoxinA. *Parkinsonism Relat Disord*. 2014;20(6):665-667.
30. Dressler D, Adib Saberi F, Bigalke H. IncobotulinumtoxinA (Xeomin®) can produce antibody-induced therapy failure in a patient pretreated with abobotulinumtoxinA (Dysport®). *J Neural Transm*. 2014;121(7):769-771.
31. Ricciardi L, Bove F, Fasano A. XEOMIN® use in patients with systemic immune reactions to other botulinum toxins type A. *Eur J Neurol*. 2013;20(3):e45-46.
32. Lorenc ZP, Kenkel JM, Fagien S, et al. IncobotulinumtoxinA (Xeomin): background, mechanism of action and manufacturing. *Aesthet Surg J*. 2013;33(1S):18S-22S.
33. Naumann M, Boo L, Ackerman A, Gallagher C. Immunogenicity of botulinumtoxins. *J Neural Transm* 2013;120(2):275-290.
34. Benecke R. Clinical relevance of botulinum toxin immunogenicity. *Biodrugs*. 2012;26(2):e1-e9.

35. Santamato A, Ranieri M, Panza F, et al. Effectiveness of switching therapy from complexing protein-containing botulinum toxin type A to a formulation with low immunogenicity in spasticity after stroke: a case report. *J Rehabil Med*. 2012;44:795-797.
36. Hefter H, Hartmann C, Kahlen U, Moll M, Bigalke H. Prospective analysis of neutralising antibody titers in secondary non-responders under continuous treatment with a botulinumtoxin type A preparation free of complexing proteins – a single cohort 4-year follow-up study. *BMJ Open*. 2012;2(4).e000646.
37. Oshima M, Deitiker P, Jankovic J, Duane D, Aoki K, Atassi M. Human t-cell responses to botulinum neurotoxin. Responses in vitro of lymphocytes from patients with cervical dystonia and/or other movement disorders treated with BoNT/A or BoNT/B. *J Neuroimmunol*. 2011;240-241:121-128.
38. Eisele KH, Fink K, Vey M, Taylor HV. Studies on the dissociation of botulinum neurotoxin type A complexes. *Toxicon*. 2011;57(4):555-565.
39. Oshima M, Deitiker P, Jankovic J, Duane D, Aoki K, Atassi M. Human t-cell responses to botulinum neurotoxin: proliferative responses in vitro of lymphocytes from botulinum neurotoxin A-treated movement disorder patients. *J Neuroimmunol*. 2011;237(1-2):66-72.
40. Frevert J. Xeomin is free of complexing proteins. *Toxicon*. 2009;54(5):697-701.
41. Dressler D, Tacik P, Saberi FA. New formulation of Botox: complete antibody-induced treatment failure in cervical dystonia. *J Neurol Neurosurg Psychiatry*. 2007;78(1):108-109.
42. Ney JP, Joseph KR. Neurologic uses of botulinum neurotoxin type A. *Neuropsychiatr Dis Treat*. 2007;3(6):785-798.
43. Dressler D, Bigalke H. Antibody-induced failure of botulinum toxin type B therapy in de novo patients. *Eur Neurol*. 2004;52(3):132-135.
44. Zuber M, Sebald M, Bathien N, de Recondo J, Rondot P. Botulinum antibodies in dystonic patients treated with type A botulinum toxin: frequency and significance. *Neurology*. 1993;43(9):1715-1718.

## Safety

1. Ioannou CI, Hodde-Chriske FL, Altenmüller E. Long-term muscular atrophy and weakness following cessation of botulinum toxin type A injections in the flexor digitorum muscle of musicians with focal hand dystonia. *Toxins (Basel)*. 2023;15(4):296.
2. Jost W, Kaňovský P, Hast MA, et al. Pooled safety analysis of incobotulinumtoxinA in the treatment of neurological disorders in adults. *Toxins (Basel)*. 2023;15(6):353.
3. Dressler D, Pan L, Saberi A. Antibody-induced failure of botulinumtoxin therapy: re-start with low- antigenicity drugs offers a new treatment opportunity. *J Neural Transm (Vienna)*. 2018;125(10):1481-1486.
4. Kazerooni R, Armstrong E. Response to "Comment on: *Clin Drug* 2018;38(12):1199-1200. Rbotulinum toxin type A overdoses: analysis of the FDA adverse event reporting system database. *Clin Drug Investig*. 2018;38(12):1199-1200.
5. Kazerooni R, Armstrong EP. Botulinum Toxin Type A Overdoses: Analysis of the FDA adverse event reporting system database. *Clin Drug Investig*. 2018;38(9):867-872.
6. Dressler D, Adib Saberi F, Bigalke H. Botulinum neurotoxin therapy: reduction of injection site pain by pH normalization. *J Neural Transm*. 2016;123(5):527-531.

7. Frait A, Vittal P, Comella C. Considerations on patient-related outcomes with the use of botulinum toxins: is switching products safe? *Ther Clin Risk Manag.* 2016;12:147-154.
8. Carey W. Incorrect reconstitution of incobotulinumtoxinA leads to loss of neurotoxin. *J Drugs Dermatol.* 2014;13(6):735-738.
9. Baizabal-Carvalho J, Jankovic J, Pappert E. Flu-like symptoms following botulinum toxin therapy. *Toxicon.* 2011;58(1):1-7.
10. Baizabal-Carvalho JF, Jankovic J, Feld J. Flu-like symptoms and associated immunological response following therapy with botulinum toxins. *Neurotox Res.* 2013;24(2):298-306.

## Clinical Pharmacology

1. Boulias C, Ismail F, Phadke CP. Acute neurophysiologic effects of botulinum toxin type A intramuscular injection on extensor digitorum brevis muscle in healthy adults. *Toxicon.* 2022;211:6-10.
2. Ledda C, Artusi CA, Tribolo A, et al. Time to onset and duration of botulinum toxin efficacy in movement disorders. *J Neurol.* 2022;269(7):3706-3712.
3. Kerscher M, Wanitphakedeedecha R, Trindada de Almedica A, Maas C, Frevert J. IncobotulinumtoxinA highly purified and precisely manufactured botulinum neurotoxin type A. *J Drugs Derm.* 2019;18(1):52-57.
4. Chen J, Dashtipour K. Abo-, inco-, ona-, and rima-botulinum toxins in clinical therapy: a primer. *Pharmacotherapy.* 2013;33(3):304-318.
5. Ricciardi L, Bove F, Fasano A. Xeomin use in patients with systemic immune reactions to other botulinum toxins type A. *Eur J Neurol.* 2013;20(3):e45-46.
6. Costa A, Pegas Pereira ES, et al. Comparative study of the diffusion of five botulinum toxins type A in five dosages of use: are there differences amongst the commercially-available products? *Dermatol Online J.* 2012;18(11):2.
7. Dressler D. Five-year experience with incobotulinumtoxinA (Xeomin): the first botulinum toxin drug free of complexing proteins. *Eur J Neurol.* 2012;19(3):385-389.
8. Fung S, Phadke C, Kam A, Ismail F, Boulias C. Effect of topical anesthetics on needle insertion pain during botulinum toxin type A injections for limb spasticity. *Arch Phys Med Rehabil.* 2012;93(9):1643-1647.
9. Kerscher M, Roll S, Becker A, Wigger-Alberti W. Comparison of the spread of three botulinum toxin type A preparations. *Arch Dermatol Res.* 2012;304(2):155-161.
10. Dressler D, Benecke R. Pharmacology of therapeutic botulinum toxin preparations. *Disabil Rehabil.* 2007;29(23):1761-1768.
11. Wohlfarth K, Müller C, Sassin I, Comes G, Grafe S. Neurophysiological double-blind trial of a botulinum neurotoxin type A free of complexing proteins. *Clin Neuropharmacol.* 2007;30(2):86-94.
12. Jost W, Kohl A, Brinkmann S, Comes G. Efficacy and tolerability of a botulinum toxin type A free of complexing proteins (NT 201) compared with commercially available botulinum toxin type A (BOTOX) in healthy volunteers. *J Neural Transm.* 2005;112(7):905-913.

## Nonclinical Comparisons

1. Byun J, Kwak S, Kwon JH, et al. Comparative pharmacodynamics of three different botulinum toxin type A preparations following repeated intramuscular administration in mice. *Toxins (Basel)*. 2022;14(6):365.
2. Kwak S, Kang WH, Rhee CH, Yang GH, Cruz DJM. Comparative pharmacodynamics study of 3 different botulinum toxin type A preparations in mice. *Dermatol Surg*. 2020;46(12):e132-e138.
3. Dressler D, Pan L, Adib Saberi F, Bigalke H. Do complexing proteins provide mechanical protection for botulinum neurotoxins? *J Neural Transm (Vienna)*. 2019;126(8):1047-1050.
4. Kutschenko A, Bigalke H, Wegner F, Wohlfarth K. The role of human serum albumin and neurotoxin associated proteins in the formulation of BoNT/A products. *Toxicon*. 2019;168:158-163.
5. Kutschenko A, Weisemann J, Kollwe K, et al. Botulinum neurotoxin serotype D – a potential treatment alternative for BoNT/A and B non-responding patients. *Clin Neurophysiol*. 2019;130(6):1066-1073.
6. Pan L, Bigalke H, Kopp B, Jin L, Dressler D. Comparing lanbotulinumtoxinA (Hengli®) with onabotulinumtoxinA (Botox®) and incobotulinumtoxinA (Xeomin®) in the mouse hemidiaphragm assay. *J Neural Transm (Vienna)*. 2019;126(12):1625-1629.
7. Frevert J, Ahn K, Park M, Sunga O. Comparison of botulinum neurotoxin type A formulations in Asia. *Clin Cosmetol Invest Dermatol*. 2018;11:327-331.
8. Di Pietro A, Piraccini BM. Frontal alopecia after repeated botulinum toxin type A injections for forehead wrinkles: an underestimated entity? *Skin Appendage Disord*. 2016;2(1-2):67-69.
9. Kutschenko A, Manig A, Reinert MC, Mönnich A, Liebetanz D. In-vivo comparison of the neurotoxic potencies of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA. *Neurosci Lett*. 2016;627:216-221.
10. Scaglione, F. Conversion ratio between Botox®, Dysport®, and Xeomin® in clinical practice. *Toxins (Basel)*. 2016;8(3).
11. Wang L, Sun Y, Yang W, Lindo P, Singh B. Type A botulinum neurotoxin complex proteins differentially modulate host response of neuronal cells. *Toxicon*. 2014;82:52-60.
12. Brown M, Nicholson G, Ardila M, et al. Comparative evaluation of the potency and antigenicity of two distinct BoNT/A-derived formulations. *J Neural Transm*. 2013;120(2):291-298.
13. Pickett A. Characteristics, properties and applications of botulinum toxins in therapeutic use today in the NHS. *Br J Gen Pract*. 2012;4(1):16-23.
14. Dressler D, Mander G, Fink K. Measuring the potency labeling of onabotulinumtoxinA (Botox) and incobotulinumtoxinA (Xeomin) in an LD50 assay. *J Neural Transm*. 2012;119(1):13-15.
15. Proietti S, Nardicchi V, Porena M, Giannantoni A. Botulinum toxin type A toxin activity in prostate cancer cell lines. *Urologia*. 2012;79:135-141. [Article in Italian]
16. Albanese A. Terminology for preparations of botulinum neurotoxins: what a difference a name makes. *JAMA*. 2011;305(1):89-90. Erratum in: *JAMA*. 2011;305(15):1544.
17. Eisele K, Fink K, Vey M, Taylor H. Studies on the dissociation of botulinum neurotoxin type A complexes. *Toxicon*. 2011;57(4):555-565.

18. Grein S, Mander G, Fink K. Stability of botulinum neurotoxin type A, devoid of complexing proteins. *The Botulinum J*. 2011;2(1):49-58.
19. Jones R, Liu Y, Halls C, et al. Release of proteolytic activity following reduction in therapeutic human serum albumin containing products: detection with a new neoepitope endopeptidase immunoassay. *J Pharm Biomed Anal*. 2011;54(1):74-80.
20. Frevert J. Content of botulinum neurotoxin in Botox/Vistabel, Dysport/Azzalure, and Xeomin/Bocouture. *Drugs R D*. 2010;10(2):67-73.
21. Frevert J, Dressler D. Complexing proteins in botulinum toxin type A drugs: a help or hindrance? *Biol Targ Ther*. 2010;4:325-332.
22. Hunt T, Rupp D, Shimizu G, Tam K, Weidler J, Xie J. Characterization of SNARE cleavage products generated by formulated botulinum toxin type A drug products. *Toxins*. 2010;2:2198-2212.
23. Carli L, Montecucco C, Rossetto O. Assay of diffusion of different botulinum neurotoxin type A formulations injected in the mouse leg. *Muscle Nerve*. 2009;40(3):374-80.
24. Hunt T, Clarke K. Potency evaluation of a formulated drug product containing 150-kd botulinum neurotoxin type A. *Clin Neuropharmacol*. 2009;32(1):28-31.
25. Mander G, Fink K, Vey M. Experimental conditions substantially influence botulinum toxin potency testing. *Clin Neuropharmacol*. 2009;32(4):234-235.
26. Tang-Liu D, Aoki K, Dolly J, et al. Intramuscular injection of 125I-botulinum neurotoxin-complex versus 125I-botulinum-free neurotoxin: time course of tissue distribution. *Toxicon*. 2003;42(5):461-469.

Xeomin and the Merz logo are registered trademarks of Merz Pharmaceuticals GmbH & Co. KGaA.

*Last updated January 22, 2025*